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Abstract
Heidi Shaffer, a MultiCare occupational therapist specializing in lymphedema (LE) management, proposed
the research question of whether bioimpedance spectroscopy (BIS) via the L-Dex (U400 Impedimed) is the most
reliable, valid, cost-effective and time-efficient assessment tool on the market for measuring LE in comparison to
circumferential measurements (CM). Shaffer currently uses the L-Dex in practice and hoped to substantiate its
psychometrics from the literature to promote its clinical usage and potentially obtain consistent insurance coverage.
A critical appraisal of the literature revealed a strong correlation between BIS and CM, suggesting that both can be
used reliably and validly in clinical practice. However, BIS can discriminate specifically betwee n intracellular and
extracellular fluid. Additionally, the research demonstrated that BIS was more sensitive, reproducible, quantifiable,
time-efficient, user-friendly and generally more widely accepted by clinicians, therapists and patients.
The knowledge translation implementation consisted of an informative in-service presentation (to
representatives of Multicare and Impedimed) and a brochure for MultiCare consumers and suggested outcome
measures for clinicians. A qualitative questionnaire was used to assess the effectiveness of the knowledge translation
process and to collect future research considerations. The outcomes suggested that there is a need for more rigorous
studies to support consistent insurance coverage of BIS. Furthermore, our findings have potential to impact
insurance coverage and to promote improved communication between healthcare professionals. researchers, and
insurance companies.
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Executive Summary
Heidi Shaffer, an occupational therapist (OTR/L) and certified lymphedema specialist (CLT-LANA)
at MultiCare in Gig Harbor, WA collaborated with students in the Master of Science in Occupational Therapy
(MSOT) program at the University of Puget Sound on a research project focused on lymphedema
measurements. The purpose of the research was to answer a question proposed by Shaffer which was refined
by the MSOT students who then produced a knowledge translation portion. The project began in September
2016 and was completed in May of 2017, taking about 9 months to complete. It was b roken down into two
parts, which consisted of 1) a comprehensive systematic review of the literature to recommend the best
lymphedema assessments and 2) translate those recommendations into practice by providing this information
to the right individuals within MultiCare. The student researchers spoke with Shaffer to determine the
research question and to identify how the question related to her clinic. The question was: “How do
perometry, bioimpedance spectroscopy (BIS) and circumferential measurements (CM) compare to one
another based on reliability, validity, cost, and time-efficiency for measuring unilateral lymphedema (LE)?
The question was inclusive of a majority of the clients seen by lymphedema specialists in their clinics.
The assessments currently used at the Shaffer’s clinic are CM and BIS. Shaffer is disappointed with
the cost to some clients due to lack of insurance coverage for the L-Dex (bioimpedance). She is also
unsatisfied with using CM because it takes 15-20 minutes longer than the L-Dex device; hence CM interferes
with potential treatment time. Her clinical reasoning leads her to believe that the L -Dex provides a more
accurate and time-efficient measure. It was her hope that the research question posed would back-up this
clinical reasoning.
The systematic review was completed as follows: 1) identified assessments that were comparable
and could be used in a clinical setting; 2) searched five online databases to ensure saturation; 3) documented
the online search process; 4) determined which assessments would be included and excluded from the review;
5) applied exclusion and inclusion criteria to include a total of 29 articles in the critical appraisal of the topic
(CAT) (3 were level I, 5 were level II, 19 were level IV, and 2 were level V studies); analyzed and compared
the psychometric properties and the clinical utility of each article. Some of the limitations of this systematic
review include: weak generalizability, difficulty comparing characteristics of assessments, small sample sizes,
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and studies involving perometry, which is rarely used in clinics (Robyn Thornburgh, personal
communication, February 10, 2017). The systematic review demonstrated that BIS is the assessment tool with
the strongest psychometric properties and would be most likely to meet the specific needs of the lymphedema
specialists conducting the administration. The strengths of BIS include sensitivity, reliability, time -efficiency
and potential for long-term cost-savings.
The next phase of the project was to conduct knowledge translation and begin implementation of the
research findings into clinical practice. The research was formally presented on two occasions to Maren Fustgaard,
Vice President of Health Economics and Reimbursement and Sherri Olsen, MultiCare Director of Wound Care. This
presentation included a review of the research found, an opportunity to report outcome measures, and which next
steps to take moving forward to encourage insurance coverage of this device. Fustgaard was pleased with our
research and the content we provided in the presentation. She gave us constructive feedback from the Impedimed
CEO and other staff members to ensure that our information regarding insurance coverage was communicated in a
clear, concise, and understandable manner. Olsen was supportive of our research findings and quickly agreed with
many of our main points. She identified that further research regarding BIS is being conducted by the oncologist
team at MultiCare. She corroborated Fustgaard’s statement about the importance of billing BIS to demonstrate to
insurance companies that there is evidence for its use in clinical practice. She asked clarifying questions regarding
our research, which we were able to answer to her satisfaction. The researchers were asked by both Fustgaard and
Olsen for a copy of the presentation, brochure, and final research paper for future reference. After viewing our
presentation and discussing the research, a survey was completed by both Fustgaard and Olsen to measure the
outcomes of the knowledge translation process. The outcome survey results indicated that our findings had potential
to be used to encourage utilization of the L-Dex and positively impact regional providers.
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Final CAT Paper
Focused Question:
How do perometry, bioimpedance spectroscopy (BIS) and circumferential measurements (CM) compare to one
another based on reliability, validity, cost, and time-efficiency for measuring unilateral lymphedema (LE)?
Collaborating Occupational Therapy Practitioner:
Heidi Shaffer OTR/L
Prepared By:
Jessica Enyeart, Cullyn Foxlee, Divina Ramolete, Connie Wyatt
Chair:
George Tomlin, PhD, OTR/L, FAOTA
Course Mentor:
George Tomlin, PhD, OTR/L, FAOTA
Date Review Completed:
11/15/2016
Clinical Scenario:
Heidi Shaffer, a MultiCare occupational therapist specializing in LE management, is wondering if BIS via the L Dex (U400 Impedimed) is the most reliable, valid, cost effective and time effective assessment tool on the market
for measuring LE. In her 12 years of LE clinical experience, she has used an array of assessments, including the
L-Dex and CM. She is relatively confident that the L-Dex is more accurate and reliable in quantifying changes in
extracellular fluid (ECF) in the limbs. Additionally, she claims that BIS is faster to administer, therefore
providing more time in the initial evaluation to treat her clients. This CAT is relevant to Shaffer because she
wants to substantiate to others (rehabilitation coordinator, MultiCare, insurance companies, etc.) with research
and evidence-based practice, that BIS is the best instrument on the market for assessing unilateral lymphedema.
Her primary issue is that most insurance companies do not cover use of the BIS, because CM are built within the
cost of the initial evaluation. Through this CAT, her aim is to compare lymphedema assessments in order to
determine if BIS truly is the best instrument, or if other assessments are shown to be better. After critique of the
literature, she hopes to utilize the evidence in such a way that the L-Dex may in the future be covered by most
insurances and that BIS may eventually become the gold standard for LE measurement instead of CM.
Review Process:
Inclusion Criteria:
LE of arms and legs, secondary LE, unilateral lymphedema, BIS, CM, perometry (including infrared
optoelectronic volumetry/perometry) and studies done anywhere in the world.
Exclusion Criteria:
Primary LE, non-human subjects, self-assessment, children, articles older than 1990, head/neck LE,
studies solely measuring early diagnosis or detection of breast cancer-related lymphedema (BCRL), water
volumetric measurements (if not compared to CM, BIS or perometry), and tonometry if not within a
systematic review/meta-analysis.
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Search Strategy
Categories
Patient/Client Population
Assessment
Comparison
Outcomes

Key Search Terms
lymphedema, lymph*, NOT breast cancer related, NOT BCRL, breast
cancer, bioimpedance
measurement, assessment, evaluation, bioimpedance, L-Dex, bioimped*,
peromet*
Circumferential measur*, comparison
Reliab*, valid*, cost, efficien*, accura*

Synonymous Keywords
Keywords

Synonym(s)

Lymphedema

Alternative spelling
Lymphoedema
LE

Assessment

Evaluation
Measurement
Measure

Bioimpedance spectroscopy

Bioimpedance analysis
Bioimpedance

BIA
BIS
MFBIA
SFBIA

Extracellular fluid

Extracellular water

ECW
ECF

Circumferential
measurements

Frustum sign method
Disk model method
Anatomical landmarks
Wrist to axilla measurement

FSM
DMM
CM
CMAL

Perometry

Optoelectronic volumetry
Optoelectronic perometry
Infrared optoelectronic perometry
Infrared optoelectronic volumetry
Databases & Sites Searched
PubMed – 14 searches
Primo - 4 searches
AJOT - 2 searches
OT Search – 1 search
PEDro - 1 search

Quality Control/Review Process:
In order to get the most comprehensive searches in the amount of time allotted, our team used five
databases (listed above) to search the evidence. Our searches began broad, using keywords like
lymphedema measurements and began to narrow (using specific types of lymphedema measurements) as
our comprehension of lymphedema assessments increased. Many results from general keywords we used
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were broad and often not related to the research question. In one search, “comparison” was used to narrow
and specify a search. Through reading the evidence and consulting the clinician (Heidi Shaffer), our team
began to comprehend what types of lymphedema measurement tools are used. We further refined our
search criteria as we began to find data that repeatedly reported positive outcomes for the use of BIS,
perometry, and CM. We also applied reference tracking and citation tracking methods to some articles
we’d already found, but those did not yield a high volume of different results due to the extensiveness of
our database searches. Articles found from reference tracking and citation tracking were only included if
they were duplicates or had a measurement comparison. Articles with titles indicating that only one form
of measurement studied were not included because the articles including only one measurement we already
had provided the background we needed. Our search became saturated with the same articles , at which
time, we concluded our reference tracking searches. Also, following examination of Perdomo et al. (2014),
our team is considering changing our exclusion criteria to articles published prior to 2001.
There were 1504 articles found, 1400 rejected, 79 were duplicates with 25 reviewed and placed into our
critical appraisal of topics table on October 25th, 2016. After further review on November 13th, 2016, 2
articles from reference checking, and 1 article that came in late from an ILLIAD request (fro m a database
search) were added to the table, making 28 the total number of articles placed into the CAT. Many articles
that were rejected studied only early detection/diagnosis of BCRL and Shaffer was not interested in using
assessment tools to diagnose or detect LE. Other articles were rejected because they studied treatments for
LE rather than assessments or measurements of LE. Unfortunately, some articles were excluded because
they could not be requested via ILLIAD, hence further exploration to obtain these studies is required.
These potential articles were checked and determined not to fit the criteria for review.
Additional and relatively new studies (Soran et al., 2014; Laidley and Anglin, 2016) were included in the
CAT on April 12, 2017. They were provided to us in a meeting via Impedimed’s Vice President of Health
Economics and Reimbursement, Maren Fustgaard. The addition of these articles helps to provide more
comparison between CM and BIS, highlights subclinical LE and expands on the clinician and patient
implications regarding BIS. These articles may not have been found or considered within our search
strategies due to many reasons including: the exclusion criteria of early-detection, limited accessibility to
specific journals, and cost. Although these studies address early detection, their results and implications
strengthen and support the literature analyzed in this project. An article was removed on April 17, 2017
because after close examination of the statistics, it did not appear to have included all information
necessary to draw conclusions.
Shaffer is the clinician overseeing this research due to her desire to provide better practice for her clients
and her clinic. All outstanding questions (from team members) concerning Shaffer’s preferenc es for the
research question were directed to her via email. Eli Gandour-Rood, a library liaison, aided in search
strategies and alternative options for searches; one member of our team met with him on Friday, October
14, 2016. George Tomlin provided our team with essential one-on-four statistical guidance/knowledge,
search strategies and organizational techniques. Also, all other questions that the team members could not
find an answer to were directed to George Tomlin. Jessica Enyeart, Cullyn Foxlee, Divina Ramolete, and
Connie Wyatt put in time to ensure a fluid plan was in place for this critical appraisal. It took an abundance
of coordination among team members to ensure that data was collected in a structured manner.
Results of Search
Table 1. Search Strategy of databases.
Search Terms

Date

Database

Initial
Hits

Articles
Excluded

Total Selected for
Review

(Lymphedema) AND (Measurement)

09/20/16

PEDro

12

12

0

Lymphedema measurement:
similar articles via Hidding et al

09/20/16

PubMed

375
96

375
88

n/a
8
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(2016)
lymphedema [and] measurement

09/22/16

AJOT

10

10

0

Lymphedema measurement
Redone: additional term: comparison

09/22/16
10/19/16

Primo

321
36

321
31

n/a
5

lymphedema measurement (category:
Master’s thesis)

09/22/16

OT
Search

0

0

0

Lymphedema AND measurement

09/22/16

PubMed

374

371

3

lymph* AND measur*

09/22/16

Primo

148

147

1

Bioimpedance AND cost AND
lymphedema

09/27/16

PubMed

4

2

2

Bioimpedance AND efficiency AND
lymphedema

09/27/16

PubMed

0

0

0

Bioimpedance AND accura* AND
lymphedema

09/27/16

PubMed

14

8

6

Bioimpedance AND reliab* AND
lymphedema

09/27/16

PubMed

15

13

2

Circumferential measur* AND
lymphedema AND bioimpedance

09/27/16

PubMed

5

3

2

Circumferential measur* AND
lymphedema AND efficien*

09/27/16

PubMed

2

2

0

Circumferential AND measurements
AND lymphedema

10/17/16

Primo

41

40

1

Lymphedema AND peromet* AND
(assessment OR evaluation OR
measurement)

09/28/16

PubMed

51

43

8

((((Lymphedema) AND measurement)
NOT BCRL) NOT Breast cancer
related)

10/06/16

PubMed

287

275

12

((Lymphedema) AND measurement)
AND bioelectric impedance

10/12/16

PubMed

2

2

0

circumferential AND measurements
AND lymphedema AND reliability

10/16/20
16

Primo

10

9

1

Lymphedema AND peromet*

10/17/16

PubMed

68

58

10

Deltombe, Jamart

10/17/16

Primo

24

23

1

Lymphedema & water displacement

10/23/16

PubMed

25

23

2
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volumetry
Of the 64 articles found, 43 were duplicates.
Total number of articles used in review from database searches = 21
Table 2. Articles from Impedimed website (https://www.impedimed.com/products/l-dex-u400/)
Article

Date

Shah et al., (2013)

10/14/16

Ward et al., (2008)

10/14/16

Direct correspondence with Catherine Kingsford and Reuben Lawson from Impedimed led us to explore article
titles and authors shared on their website. They also suggested articles to research via email. Authors and titles
were then plugged into Primo or Google Scholar to be reviewed.

Of the 15 articles found, 13 were duplicates from the database searches above.
Total number of articles used in review from Impedimed website searches = 2
Table 3. Articles from citation tracking.*
Article

Date

Database

Initial Hits

Articles
Excluded

Total Selected for
Review

Deltombe et al (2007)

10/17/16

PubMed

18

16

2

Fu et al (2014)

10/18/16

PubMed

6

6

0

Of the 2 articles found, 2 were duplicates from the database searches above.
Total number of articles used in review from citation tracking = 0
*Articles were not further reviewed if the title suggested that only one measurement tool was studied in an article
because the focus of our research is the comparison of different measurement tools.
Table 4. Articles from reference tracking.*
Article

Date

Articles Referenced

Articles Excluded

Total Selected for
Review

Seward et al., (2016)

10/14/16

30

25

5

Smoot et al., (2011)
(not used in CAT)

10/15/16

25

21

4

York et al., (2008) [This
should stay because we used
it for reference tracking]

10/18/16

17

15

2

Czerniec et al., (2010)

10/20/16

28

21

7

Perdomo et al., (2014)

10/20/16

82

77

5
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Fu et al., (2013)

10/20/16

29

27

2

Adriaenssens et al., (2013)

10/28/16

38

27

11

Hayes et al., (2008)

10/28/16

25

22

3

Bilir et al., (2012)

11/11/16

43

40

3

Hidding et al., (2014)

11/11/16

70

53

17

Jain et al., (2010)

11/13/16

29

24

5

Of the 64 articles selected for review, 59 were duplicates from the database searches above.
Three articles were eliminated due to not meeting inclusion criteria.
Total number of articles used in review from reference tracking = 2
*Dups = Duplicates of articles used in CAT
*Articles were not further reviewed if the title suggested that only one measurement tool was studied in an article
because the focus of our research is the comparison of different measurement tools.
Total number of articles used in review from database searches = 21
Total number of articles used in review from Impedimed website = 4
Total number of articles used in review from citation tracking = 0
Total number of articles used in review from reference tracking = 2
Total number of articles used in review from UPS Master’s Thesis = 0
Total number of articles used in review from Impedimed Vice President = 2
Total number of articles used in CAT = 29
Summary of Study Designs of Articles Selected for the CAT Table
Pyramid Side

Outcome

Descriptive

Study Design/Methodology of Selected Articles

Articles Selected

2 Systematic Reviews of Related Outcome Studies
0 Individual Quasi-Experimental Studies
5 Case-Control Studies
0 One Group Pre-Post Studies

7

1 Systematic Reviews of Related Descriptive Studies
19 Association, Correlational Studies
2 Multiple Case Studies (Series), Normative Studies
0 Individual Case Studies

22

AOTA Levels
I- 3 articles
II- 5 articles
IV- 19 articles
V- 2 articles
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Systematic Reviews
Author, Year

Study
Objectives

Study
Design,
Level of
Evidence

# of papers, inclusion/exclusion
criteria

Interventions &
Outcome Measures
Quality Assessment of
Diagnostic Accuracy Studies2 (QUADAS-2): Used to
document concerns regarding
applicability and amount of
bias. Four components of
methods are scored w/ the
following method:
Likely applicable or bias
unlikely= “+”
Probably applicable or bias
possible= “?”
Probably not applicable or bias
very possible= “-“
Reliability: (95% confidence
for all the following)
CM (tape measure) for upper
extremity:
IAR: ICC=0.99 CI: 0.99-0.99
IER: ICC=0.98 CI: 0.98-0.98
BIS IAR: 0.88-0.99
OP for upper extremity: IAR:
ICC=0.99 CI: 0.97-1.00
Volumeter for upper extremity:
IAR/IER: ICC=0.99 CI: 0.990.99
Concurrent validity:
(WD used for comparison)
WD to CM range: 0.80-0.99
I: CM, WD, tonometry, BIS,
OP, & self-report

Hidding
et al.,
(2016)
PT

Determine
which LE
measurements
have the best
reliability &
validity for a
given stage of
LE

Systematic
Review
D1
Level I

27 studies
The following measurements were
compared more than once: BIS: 3,
MFBIA: 3, WD: 10, CM: 12, OP: 3,
Tonometry: 3, Self-report: 2
The following were only seen once:
Moisture Measure: 1, Goniometry: 1
Inclusion criteria: Measurements
performed X2, comparisons of
assessments
Studies: Case
control/prognostic/cross-sectional
Language of study:
English/Dutch/German/French
Quality: The Quality Assessment of
Diagnostic Accuracy (QUADAS-2)
Exclusion criteria: X-ray
absorptiometry, tomography*, &
goniometry*, patient-reported
questionnaires, CG sig younger M
age than affected population
*These assessments were included,
but never w/o being compared to at
least one other assessment

Perdomo et al.,
(2014) RO

Identify
specific
assessment
techniques
recommended
for use in
clinical
practice to

Systematic
Review
O1
Level I
EDGE form
used to grade
all studies

51 papers: 13 CM, 9 WD, 3
tonometry, 10 BIS, 13 OP, 3 selfreport; 2001-2012; 15 databases;
Inclusion: UE, secondary LE, adult,
F, breast neoplasm; Exclusion:
Languages other than English,
primary LE, lower extremity,
venous, male, MRI,
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OM: Breast Cancer EDGE
form based on IAR, IER, CC,
sensitivity, specificity (ROC
curve), SRD, SEM, CI, LAA,

Summary of Results

Limitations

BIS is ideal for detection in earlier stages of
LE because it is sensitive enough to identify a
change at first stage LE. Variations in the 2nd
stage of LE can be identified by other physical
measurements. OP, WD, & CMs all have high
IAR. WD has a high concurrent validity w/
BIS & CMs. Studies reviewed support these
assessments of LE as effective tools for
measuring LE.

LE is defined
differently by
different studies.
Most studies were
not blinded studies,
which might have
eliminated bias.
Participant
exclusion/inclusion
criteria not always
clear.

Edge scores of importance: 4 = highly
recommended, good psychometric properties
& good clinical utility, has been used in BC
research; 2A = Unable to recommend,
insufficient info to support tool, although
measure has been used in BC research;
CM, WD & BIS scored an EDGE 4 while
tonometry, OP, & self-report scored an EDGE

Potential to be more
extensive &
informative; doesn’t
explicitly specify
studies used in
review

11

Seward et al.,
(2016) JSO

measure UE
secondary LE
in BCS
Analyze
advantages,
disadvantages
& results of
studies w/
evidence base
for detection
& measure of
BCRL using
BIS

lymphoscintography, CT scan,
ultrasound, Doppler
Comprehensive
Review
O1
Level I

2A

23 studies: SFBIA vs CM (3),
SFBIA vs MFBIA (3), BIS vs OP
(6), MFBIA vs CM/WD (7), BIS vs
2 or more other techniques (4).
1992-2015. Inclusion: Studies w/
direct analysis of BIS related to
BCRL. Exclusion: not stated.

I: SFBIA, CM, MFBIA, BIS,
WD
OM: Psychometrics (specifics
not stated)

BIS is an effective tool for well-established
BCRL. SFBIA less accurate than MFBIA; BIS
use combined w/ volumetric techniques could
yield max benefits for all patients. One study
showed that BIS can detect edema as early as
10-months sooner than CM. 100% sensitivity
& 98% specificity. Other studies show no
statistical difference seen b/w LG & CG using
BIS. BIS reported false negative rate of 27% in
one study. Results vary highly. BIS results are
best read as resistance ratios & are less
accurate when converted to volume.

No grading tool used,
methods section is
one sentence, tables
describing studies
need more info.

Bioimpedance Spectroscopy and Optoelectronic Perometry compared to one another (* indicates studies where CM was also include d)
Author,
Year
Bundren et
al., (2015)
BCRT

Study Objectives
To determine the best
method of detecting
LE after axillary
surgery

Study Design,
Level of
Evidence
Correlational
D2
Level IV

LYMPHEDEMA ASSESSMENTS

Assessments
OP & BIS (L-Dex
U400)
LV measured pre BC
axillary surgery and
post for at least 6
months, analysis for
this current report
involved comparison
of the baseline (pre)
and 1-month postsurgery

Psychometrics
Paired t-tests used for
comparison
Using pre-operative
measurements as baseline: OP
detected 52 patients w/ LE by 6
months, when using 1-month
post measurements as baseline,
OP detected 43 patients w/ LE
by 6 months but 12 were
different patients so there was
only 31 in agreement
Using pre-operative
measurements as baseline: BIS
detected 106 patients w/ LE by 6
months, when using 1-month
post measurements as baseline,
BIS detected 67 patients w/ LE
by 6 months, there were 53 in
agreement
Pre-operative BIS score mean
was -0.16 (range -22.10, 26.90),
1-month post BIS score mean

Population,
Setting
612 women (M age
= 55 y.o)
undergoing surgery
for BC were
recruited from 7
centres across the
UK between July
2010 and May
2014. 42 % had
undergone
mastectomy

Summary of Results

Limitations

These results show the need for
pre-operative measurements to
be taken and used for baseline
measures prior to treatment.
This will allow for clearer
indications for the effects of
treatments on the development
of LE. This is contrary to what
is currently occurring
internationally, with medical
insurance refusing to pay for
pre-operative BIS
measurements, saying that 1month post-operative measures
are sufficient.
This current data comparing
pre-operative w/ 1-month postoperative OP and BIS
measurements have shown
significant difference between
these 2 time points.
Both OP and BIS appear to

True and false
positive & true and
false negative values
were not reported
clearly
This is only the first
analysis of what will
be a five year followup with patients
when complete, so
the final data will be
more definitive,

12

was 2.86 (range -17.50, 53.40), p
< 0.005
Pre-operative OP score mean
was 4.43 ml (range -514, 580),
1-month post OP score mean
was 33.22 ml (range -493, 623) p
< 0.005
Moderate correlation between
OP and BIS at 3 months (r =
0.40) and 6 months (r = 0.60)
Sensitivity = 73 % (95% CI:
0.59-0.84)
Specificity = 84 %(95% CI: 0.80
-0.87
*Czerniec et
al., (2010) CI

To compare the
physical methods of
LE (BIS, OP, &
truncated cone)

Correlational
D2
Level IV

LYMPHEDEMA ASSESSMENTS

VAS-Self-report
BIS
OP
Truncated cone
method

CI: 95% for the following
data:
Reliability of Physical
Measures on Affected
Extremity:
OP:
LG ICC: 1.00 (CI: 0.99-1.00)
CG ICC: 1.00 (CI: 0.99-1.00)
BIS:
LG ICC: 0.95 (CI: 0.90-0.98)
CG ICC: 0.81 (CI: 0.56-0.93)
Truncated cone CM:
LG ICC: 0.98 (CI: 0.96-0.99)
CG ICC: 0.98 (CI: 0.95-0.99)
Correlation b/w Physical
Measures & Other physical
measures:
truncated cone v. OP:
Total limb:
CC=0.98
Limb difference: CC=0.99
Inter-limb ration: CC=0.98
BIS v. truncated cone:
CC=0.89
BIS v. OP:
CC=0.92
BIS (.99) had higher IER than
CM (.98)

indicate that there is a degree
of over and under diagnosis of
LE if 1-month post-operative
measurements are used rather
than pre-operative

English speaking
women w/ BC tx
induced unilateral
arm LE: 33
CG: Women w/o
BC or LE or
medical history of
either condition: 18
Exclusion:
Pregnant women
&/or pacemaker (or
other built-in
device)
Participant
recruitment
involved
advertisements &
media releases.

Physical methods: high
agreement w/ each other
Physical measurements:
moderate agreement w/ VAS
Physical measurements had
both high IAR reliability &
IER reliability.
BIS: higher IER than truncated
cone measurement; is the more
sensitive measure when
compared to OP and truncated
cone measurements in
detecting differences
unilaterally
Physical measures cannot
replace each other for a single
patient; not interchangeable
Truncated cone method
underestimated volume
compared to OP

OP could not
measure the entire
length of arm on 11
participants w/ LE &
7 w/o. Not a blind
study, so it was
known who had LE
& who did not. This
could have caused
bias in the
measurements
reported from the
researchers since
they knew who had
LE and thus knew
from whom a change
would more likely be
seen.
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Czerniec et
al., (2009)
SCC

To determine if BIS
can detect localized
LE of arm & compare
BIS measures w/ OP

Correlational
D2
Level IV

OP (peroplus
software) & BIS (Imp
RSM version 1.12.0 &
Bioimp Version 2.25
Impedimed Ltd)
Measured up arm
starting at ulnar styloid
process - 0-10cm, 1020cm, 20-30cm, 3040cm

LCC: (rc = 0.86) CC among arm
segments varied (rc = 0.46 to rc
= 0.78)
LAA: Bias ranged from 10% to
16% among segments. Bias was
positive toward BIS on all 4
segments
ANOVA: sig difference b/w
groups (F(1, 38) = 9.256; p
=.004), b/w BIS & OP (F(1, 38)
= 11.552; p =.002), sig
interaction b/w groups &
assessments (F = 8.926; p =.005)
As expected, both instruments
showed results when
lymphedema was present. BIS
was also more sensitive in
detecting lymphedema when
compared to OP.

29 F w/ mild to
severe upper limb
LE (M age: 60); 11
F w/ no hx of LE
(M age: 53.5).
Inclusion:
understand English;
Exclusion:
Pacemakers, inbuilt
stimulator,
pregnancy

BIS is able to detect localized
changes with a higher degree of
sensitivity than total LV
measures; this is because BIS is
designed to differentiate b/w
ECF & other fluids which
allows BIS to detect localized
LE more readily than OP. BIS
can detect LE before it
manifests as a total LV change.
Segmental BIS is not
recommended, but rather whole
arm measures.

4 F weren’t
measured @ 3040cm due to arm
length/trunk shape;
cut-off values for
BIS & OP for whole
arm may not be
applicable to
individual segments;
normative data for
limb segments need
to be established; no
preoperative data.
No direction of
differences reported.

Dylke et al.,
(2016) AO

Determine which
normatively
determined &/or
commonly used
diagnostic thresholds
are optimal for
diagnosis of LE when
compared to
lymphoscintigraphy

Correlational
D2
Level IV

OP (Peromerter,
1000M Juzo) & BIS
(SBF7, Impedimed
Ltd.) &
Lymphoscintigraphy

ANOVA & ICC
Limb ratio determined by
comparison of A & U arms.
IAR of dermal backflow scoring
= ICC: 0.957, 95% CI 0.8850.984
M OP inter-LV difference
increased consistent with dermal
backflow score (f = 88.32, p <
0.001)
Diagnosis of LE with BIS & OP
sig better compared to
lymphoscintigraphy (x2 = 25.863.8, p < 0.05) Specificity range
67%-94%. Sensitivity range =
92-100%.

68 F recruited
through open
advertising. 68
women previously
treated for LE
(LG), 13 without
BC or LE (CG), 6
with hx of BC but
no LE (BC group)

IAR of dermal backflow
scoring was found to be
excellent.
58% of women in LE group
had severe dermal backflow
OP LV increased with dermal
backflow score increase
Diagnosis of LE by OP & BIS
was excellent compared to
Lymphoscintigraphy.

Lacking detail about
participant’s medical
hx, demographics &
presentation.
Almost ½ of the LE
groups data could
not be used due to
excess dermal
backflow levels

Jain et al.,
(2010) (L)

1.Establish the IER &
IAR of BIS

Correlational
D2

BIS & OP

Raw data values for both BIS &
OP were converted into ratios of

Convenience
sample of 10 F

Sig differences b/w BIS values
of A & U arms based on

Study was limited to
10 participants due

LYMPHEDEMA ASSESSMENTS
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2.Establish
concurrent validity of
BIS compared to OP
when determining
ratios of affected
limbs to unaffected
limbs

Level IV

A to U limbs for comparison.
Paired t test used to compare
volumes obtained by both
measures. Linear correlations
b/w BIS ratios for A & U arms
calculated for two trials of rater
2(R2) & b/w measurements of
rater 1(R1) & first trial (T1) of
R2 to determine IER & IAR.
IER & IAR reliabilities of raw
BIS scores examined by ICC.
Concurrent validity against OP
determined by calculating linear
correlations b/w A & U ratios for
OP & BIS.
IER agreement b/w R1 & R2, r
=0.987, p < 0.005 with BIS
IAR for R2, r = 0.993, p < 0.005
ICC for raw data of A & U arms
ranged from 0.969 to 0.996
within & b/w raters.
OP ratios were inversely & sig
correlated with BIS ratios range
r = -0.89 to -0.90 , p <0.005

volunteers recruited
through Nat. BC
Support
Organization.
Ages 49-67 y.o
8 Caucasian, 1
African America, 1
Hispanic
All were right hand
dominant, 4 with
pathology on right
side

measurements by R1 & T1 &
T2 of R2
OP identified sig volume
differences b/w A & U arms.
IER b/w R1 & R2 was very
good
IAR for R2 was very good
ICC for raw data of A & U
arms within & b/w raters was
good.

33 (28 F, 5 M) w/
secondary LE (M
age: 59) Inclusion:
ability to stand for
2 mins, to abduct
hips, to hold leg
horizontally for 1
min. Exclusion: not
listed
N=25
LG: 11
CG: 14

MFBIA is more accurate for
limb fluid change. OP is more
accurate determination of total
LV change. Both are equally
valid in measuring leg volume
changes. Both OP & BIS are
non-invasive, easy & quick
methods to assess secondary
lymphedema.
Strong correlations b/w BIS
methods; Strong correlations
b/w CM & OP

Moseley,
Piller &
Carati (2002)
(L)

To determine
effectiveness of OP
compared w/ MFBIA

Correlational
D2
Level IV

OP & MFBIA;
baseline taken prior to
3 week home LE
program & measures
taken each week & 1
month post tx.

Pearson correlation analysis:
OP & MFBIA:
r = 0.611 (p<0.001);
r = 0.495 (p<0.004) for changes
measured by both;
MFBIA: internal consistency w/
change in ECF (r = 0.427, p
<0.001).

*Ridner et
al., (2007)
(L)

To examine
relationship b/w CM,
OP, & BIS

Correlational
D2
Level IV

CM via tape measure
wrist to axilla (25min)
OP via perometer

1 visit, 60-90-minute data
collection session; 3
measurements for each

LYMPHEDEMA ASSESSMENTS

OP & BIS ratios were inversely
& sig correlated
Data indicates that BIS is able
to produce reliable IER & IAR
measurements & there is
concurrent validity b/w BIS &
OP

to BIS being
considered
“investigational” at
the time
Small sample size
BMI for patients
varied widely
BIS is unable to
restrict
measurements to a
single segment of the
limb whereas OP &
CM can

lack of statistics, old
article, no control
group, MFBIA taken
during standing

Participants unclear;
male/female?
Cannot generalize
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350S (5 min)
BIS via
LYM & EIS (6 min)
LYM: single
frequency provides
difference in fluid b/w
affected & unaffected
limbs
EIS: multi-frequency

Ward et al.,
(2009) LRB

To assess agreement
b/w BIS indices &
inter-limb volume
differences via OP

Correlational
D2
Level IV

LYMPHEDEMA ASSESSMENTS

Both arms of each
participant measured.
BIS Indices: (SFB7;
impedimed) →
impedance ratio of
extracellular fluid only
Single frequency
impedance monitor
(model XCA;
impedimed) → L-dex
score (conversion of
SFB7)
OP: (Perometer 350S)
→ 40cm volume
% of unaffected arm
volume corrected
3.6% for limb
dominance (total limb
volume)

arm/assessment→ averaged
CM & OP: r = 0.877
CM & EIS: r = 0.708
CM & LYM: r = 0.727
LYM & EIS: r = 0.987

OP calculated via Peroplus
software, relationships assessed
by correlation & LAA analysis
LG:
Impedance ratio: 1.273+/- 0.245
L-dex: 25.6+/-24.9
Arm 40cm segment volume ml:
Affected: 2572+/-757
Unaffected: 2095+/- 586
CG:
Impedance ratio: 1.016+/- 0.046
L-dex:1.4+/-5.9
Arm 40cm segment volume:
Dominant: 1964+/-478
Non dominant: 1924+/-502
r = 0.926 b/w impedance ratio,
L-dex score & OP of both groups
r = 0.919 b/w impedance ratio,
L-dex score & OP of LG group

Inclusion: CG→
age 18+, no history
of lymphedema,
capable of
informed consent
LG: 18+ y.o,
diagnosis of
unilateral
lymphedema, selfreported history of
lymphedema or
swelling prior to tx
Exclusion:
pregnancy,
pacemaker,
implants, allergies
to electrodes

Women from
Breast Cancer
Research Group
LG: 45 women w/
unilateral
lymphedema
CG: 21 women w/
no history of
lymphedema
Women from
Breast Cancer
Research Group
Inclusion:
Unilateral
lymphedema as a
consequence of tx
for breast cancer
Exclusion:
Pacemaker,

Less strong correlations
expected b/w BIS, CM, & OP;
further validate different
measurement approaches;
Recommend consideration of
time when choosing an LE
assessment

due to small sample
size, participants
measured only one
time & menstrual
cycle status not
considered which
may affect lymph
ratios
Different data
collectors for CM
Dominant vs. nondominant limb ratios
not included; unclear
what impact this may
have.

BIS & OP strongly correlated;
BIS can be converted to
volume measurement
Generally good LAA except
for
classification; methods not
interchangeable but can be
used independently
Lower validity w/ OP would
not detect lymph close to axilla
BIS detected greater difference
when arm lymph differences
were larger vs. OP; BIS
reflected specificity &
sensitivity to detect changes in
ECF
Recommends BIS use for early
stage lymphedema when
changes are predominantly in

CG younger &
weighed less than
LG group; did not
control for these
covariates
LAA are unclear;
data needed to be
scaled 0-100; article
states both poor &
generally good LAA
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pregnant

extracellular fluid
Both suitable, rapid to perform
& noninvasive to pt; BIS
cheaper

Bioimpedance Spectroscopy compared to Circumferential Measurements and/or Water Displacement
Author, Year

Study Objectives

Cornish et al.,
(1996) BCRT

Investigated
application of
MFBIA to monitor
LE volume in UE
limbs diagnosed w/
LE following BC
surgery

Fu et al.,
(2012) (L)

To estimate
reliability,
sensitivity,
specificity & AUC
for cross sectional
assessment of BIA
to detect arm LE &
relationship b/w
BIA & CM

Study Design,
Level of
Evidence
Pre-existing
groups
comparison
O3
Level II

Pre-existing
groups
comparison
O3
Level II

LYMPHEDEMA ASSESSMENTS

Assessments

Psychometrics

Population, Setting

CM & MFBIA
(Swept frequency
bioimpedance 2)–
Daily schedule w/
compression
therapy/bandaging
& massage for 4
wks. Daily MFBIA
& CM measures
taken during 1st 4
wks.

LAA:
CG:
3.1% bias
Patient:
15-21% bias
Mann-Whitney 2-sample test:
MFBIA: CI: -3.3%
<ECW<10.5%. CM:
-7.5%<Volume ratio< 12.5%.

University of Queensland:
20 F w/ no hx of LE
(university staff) (M age:
40); 20 F w/ grade 2
unilateral LE (M age: 60).
Inclusion Criteria: age 18+

BIA & CM (TestRetest 3x @ 5 min
intervals).
BIA Specifics à
Imp XCA® Impedimed;
>30kHz; L-Dex
Ratio used;
electrodes placed on
dorsum of R & L
wrists adjacent to
ulnar styloid process

Strong agreement among all 3
measures: ICC: CG & at-risk
groups (ICC: 0.99 (CI: 0.990.99)); Fair agreement among
all 3 measures for LG: ICC:
(ICC: 0.69 (CI: 0.58-0.82)).
Sensitivity & Specificity:
Discriminating b/w CG & LG;
AUC of 0.975 (CI: 0.951-0.999;
p<0.001) Discriminating b/w atrisk & LG: AUC of 0.941 (CI:
0.907-0.976; p<0.001). Using
L-Dex ratio >+10

60 F w/ no hx of LE (CG)
(M age: 36.5); 42 F w/
BCRL (M age: 58); 150 F
BCS @ risk for LE (M age:
55.8); Inclusion: English,
age 18+; Exclusion: Bilateral
breast disease, recurrent
cancer, artificial
limb/knee/hip, &
kidney/heart failure. (BIA
not accurate under these
conditions) All participants
recruited in NYC

Summary of Results

Limitations

MFBIA & CM measures
different physiological
quantities; not scalar
quantities of each other.
MFBIA, which measures
actual ECW, has greater
sensitivity & precision in
detecting changes than an
assessment tool which
measure total LV (i.e., CM).
MFBIA also measures
ICW. MFBIA has been
shown to be more sensitive
to lower levels of LE &
monitoring changes to tx
response. MFBIA offers a
technique that is more
discriminatory, sensitive,
reproducible, and
quantifiable than CM.
BIA using L-Dex is a highly
reliable method to assess
LE among healthy women
& BCS at-risk for LE;
reliability was acceptable
for survivors with LE.
There was a sig correlation
b/w BIA by Imp XCA(R) &
CM, which indicates that
both can be used to measure
LE in clinical practice.
Also, the BIA by Imp
XCA(R) is time efficient

No sensitivity or
specificity
psychometrics; old
article implies that
newer statistical
options now &
upgraded BIA
equipment now; no
baseline measures

Characteristic
differences among
CG, at-risk & LG;
no baseline BIA
measure prior to
cancer surgery; no
follow-up measures
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Ward (2006)
LRB

Present evidence
that BIA is a
sensitive & accurate
instrument suitable
for measuring LE

Opinion Paper
D2
Level V

BIA, CM & WD

discriminating b/w CG & LG
yielded AUC of 0.86 (CI: 0.760.91); sensitivity=0.66 (CI:
0.51-0.79); specificity=0.99 (CI:
0.93-0.99); discriminating b/w
at-risk & LG yielded AUC of
0.81 (CI: 0.76-0.91)
sensitivity=0.66 (CI: 0.51-0.79);
specificity=0.95 (CI: 0.90-0.98);
BIA & CM (r = 0.44; CI: 0.160.66; p <0.01)
Variation for repeat
measurements: BIA
0.60(15.4%), CM 2.1(35%)
Low inter-rater variability in
BIA
Speed to administer: BIA = 1
min, CM = 7 min
Sensitivities: CM = 35%, BIA
= 65%.
Corresponding specificities:
CM = 88.5%, BIA = 76.9%

metropolitan cancer center &
NYC metropolitan
community.

(<5 mins to administer) &
requires no certification to
operate & L-Dex ratios take
into consideration inherent
differences b/w dominant &
non-dominant limbs.

This is an opinion paper and
does not include any details
of the subjects from the
studies referenced other than
that they were women with
LE and had undergone
surgery for BC at some
point.

BIA is found to be faster,
more consistent, better
accepted by clinicians,
therapists & patients, than
WD or CM. It is portable,
relatively inexpensive &
can be administered by nonspecialist personnel.

BIA is still
considered novel
Does not provide
information about
settings or
populations studied
by the articles the
information is
gathered from

Bioimpedance compared with itself
Author, Year
Shah et al.
(2013) (L)

Study Objectives
To examine if BIS
can detect changes
in lymphedema
following tx for
BCRL

Study Design,
Level of
Evidence
Pre-existing
groups
comparison
O3
Level II

LYMPHEDEMA ASSESSMENTS

Assessments
BIS (L-Dex U400)
Scores monitored
baselineàpostsurgery

Psychometrics

Population, Setting

tx interventions outcome
measures
BCRL tx: M change L-Dex
score baseline to 1st postsurgery = 8.1+/-7.3
W/o tx:
M change L-Dex score baseline
to 1st post-surgery = 1.6+/-5.8
Sig. reduction in M L-Dex score
p=.001 following BCRL tx (5.8) vs. CG (0.1) For Subset
group
Sig. reduction p=.005 in M LDex score from 1st post tx to
last tx when comparing BCRL

N=50 participants data
from 3 centers that
used L-Dex U400
BCRLtx: 13
CG W/o tx: 37
Subset group N=32 of
50 w/elevated L-Dex
scores post-surgery
BCRL tx:11 of 32
W/o tx: 21 of 32
Inclusion: diagnosis of
BC, 18+ y.o,
underwent
lumpectomy or

Summary of Results
BIS found to be valid in
detecting early onset
lymphedema after BC surgery
& monitored reduction in LDex scores post-BCRL tx

Limitations
Did not describe
specifics of BCRL tx
or W/o tx.
Retrospective review
subject to bias of
analysis.
Lacks long-term
follow up & L-Dex
scores; definitive
conclusions due to
small sample size.
No standardized time
points tracked
measurements.
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tx (-4.3+/- 5.5) & CG (.0.1+/4.25)

Warren et al.,
(2007) APS

To establish the
reliability &
validity of BIS as
an assessment of
LE in a population
including lower
extremity, upper
extremity &
congenital LE w/
mild to severe LE.

Normative
D3
Level: IV

BIS
No comparison

Flow impedance from affected
upper extremity or lower
extremity, to unaffected upper
extremity or lower extremity
respectively:
LG:
Average: 0.9
Range: 0.67-1.01
CG:
Average: 0.99
Range: 0.95-1.02

mastectomy w/SLN or
ALND, pre-surgical
(within 180 days of
surgery) & postsurgical L-Dex scores.
Exclusion: implantable
devices, bilateral
lymphedema,
pregnancy, renal/heart
failure
LG: 15 M: 55.2 y.o
Range: 39-72 y.o
Diagnoses:
Upper extremity LE: 9
Unilateral lower
extremity LE: 4
Bilateral congenital
LE: 2
LE symptoms
reported:
M: 8.5 y.o
Range: 3 months-40
y.o
CG: 7
M: 26.9 y.o
Range: 25-34 y.o
Setting: Medical
Center

BIS yields negative different
average ratios for LG & CG.
This difference b/w LG & CG
indicates BIS can be used to
assess changes in swelling of
limbs with lymphedema. It was
noted that in some bilateral
lower extremity patients w/
specific complications BIS did
not appear to be a good
diagnostic tool

Bilateral LE can
produce inaccurate
results when BIS is
used. One participant
was included who had
bilateral LE.
Some participants w/
LE were w/in the
range of the CG flow
impedance ratio.
Reasons for this are
given as mild LE & a
body-contouring
procedure.
Small study w/
participants only
recruited from one
hospital.

Optoelectronic Perometry compared to Circumferential Measure and/or Water Displacement
Author, Year

Study Objectives

Adriasenssens
et al., (2013)
(L)

To compare mobile
infrared
optoelectronic
volumetry w/ WD
and CM

Study Design,
Level of
Evidence
Correlational
D2
Level IV

LYMPHEDEMA ASSESSMENTS

Assessments
OP (1000M, PeroSustem GmbH,
Wupertal, Germany;
Peroplus Software
TM)
WD: plexiglass
water tank
9x7x75cm
CM: frustrum,

Psychometrics
OP CG Mean Volume:
dominant arm: 1771.7ml +/338ml
Non-dominant arm: 1731.4ml
+/- 324.4ml
OP LG Mean Volume:
edematous arm: 2504ml +/701.2ml
Non-edematous arm: 1996.4ml

Population, Setting

Summary of Results

Setting: Breast Clinic
of the Universitair
Ziekenhuis Brussel
(UZB)
CG: 31 (80.6%
females)
LG: 49 females
Inclusion: No shoulder
mobility restrictions,

When comparing OP, WD &
CM (all 3 methods) for the
edematous arm (LG) and the
dominant arm (CG), the
frustrum and DMM gave the
highest volume estimation. WD
& single frustrum gave the
lowest volume estimation, while
OP was in b/w.

Limitations
8 BCS without LE
were included in the
LE group.
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single frustrum &
DMM (every 4cm)

+/- 426.6ml
Three repeated measures w/
OP w/ same PT:
CG: Dominant arm ICC: 0.998
Non-dominant arm ICC: 0.997
LG: Edematous arm ICC: 0.999
Non-Edematous arm ICC: 0.998

no open wounds at the
upper limb, able to
stand w/o support

When comparing OP, WD &
CM (all 3 methods) for the nonedematous arm (LG) and nondominant arm (CG), the
frustrum and DMM gave the
highest volume estimation. WD
gave the lowest volume
estimation while single frustum
and OP were in b/w.
Due to its reproducibility, ease
of use, and arm volume
measurements, which are not at
the extreme high or low of
multiple methods, OP could be
beneficial.

30 women volunteers
age 46-79
Included: clinical
diagnosis of chronic
arm lymphedema
secondary to unilateral
breast cancer tx; from
rehab program in
department; total/
partial mastectomy
Excluded:
neoplastic process,
bilateral surgery,
recent lymphangitis,
brachial plexitis,
validity of assessments

IOV & CM via DMM highest
reliability
WD had lowest IAR & IER
IAR of CM via DMM sig better
than FSM & WD
IAR RD were lower than IER
RD for CM & WD; no
difference b/w IOV

:

Deltombe et
al., (2007) (L)

To compare IAR,
IER, RD & to
determine LAA of
lymphedema from
CM, WD, IOV of
upper limbs

Correlational
D2
Level IV

LYMPHEDEMA ASSESSMENTS

CM via FSM or
DMM calculation
WD
IOV

PT1 performed measure 2x;
IAR PT2 & PT3 performed
each measure once; IER;
analyzed via SPSS w/ ICC 95%
CI, M, SD, LAA
FSM:
IAR: 0.96
IER: 0.94
DMM, WD, IOV:
IAR: 0.99
IER: 0.99
IAR Differences
FSM: (3.2+/-4.6%)
WD: (2.9+/- 2.9%)
DMM: (1.9+/-2.9%)
IOV: (1.5 +/-1.4%)
IER Differences
IOV: (1.7+/-1.6%)
FSM: (4.8+/-3.2%)
WD: (4.5+/-3.8%)
DMM: (3.1+/-2.2%)

Time consuming: 1
hour to complete WD
measurements.
Difficulty of
positioning upper
limb vertically in
WD.
Possible errors due to
water loss.
Cannot generalize
due to 3PTs
measuring &
performing
calculating CM;
small sample size
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Mayrovitz et
al., (2000)
ASWC

Determine how LV
measured by
automatic method
compares to
standard tape
measurements

Correlational
D2
Level IV

CM & OP (Perosystem, Perometer
model 350S)

Legs: Automated volume
7.16(0.17), tape measure
volume 6.9(0.17), % difference
4.14(0.54), Correlation
coefficient 0.9777
Arms: Automated volume
2.70(0.09), tape measure
volume 2.53(0.09), %
difference 6.97(1.18),
correlation coefficient 0.961
Legs: automated edema % =
14.2 (3.5), tape measure edema
% = 15.4(4.4)
Arms: automated edema % =
19.5(4.7), tape measure edema
% = 19.8(4.6)

62 consecutive
patients referred to
outpatient LE center,
62 measured pre-tx, 30
measured post. 184
measurements total
(142 legs & 42 arms)

No sig diff b/w the two
measurements. OP had slightly
sig higher M volume estimates
overall
Close relationship exists b/w LV
estimates obtained with CM &
OP
Overall, differed by < 5% for
legs & < 7% for arms

Did not include
details of etiology,
disease duration, type
or other tx details.
May be harder to
generalize or
reproduce.
OP device initial cost
investment is
$19,500.00
Demographic
information of
participants is
missing

Bioimpedance and Optoelectronic Perometry and Dielectric X-Ray Absorptiometry
Author, Year

Study Objectives

Ward,
Czerniec,
Kilbreath,
(2009) BCRT

To demonstrate BIS
as a quantitative
assessment by
converting it to
direct units of
volume &
comparing it to
DXA & OP

Study Design,
Level of
Evidence
Correlational
D2
Level IV

LYMPHEDEMA ASSESSMENTS

Assessments

Psychometrics

Population, Setting

Summary of Results

Limitations

BIS: SFB7
Impedimed 3-1,000
kHz to predict
volume.
DXA: X-ray
absorptiometry;
total limb water
used to determine
resistivity
coefficients.
OP: 350S; volume
estimation

BIS predicted M increase in
tissue fluid of 421+/-384ml in
affected arm of LG
Proportional increase in TF of
BIS 26.8+/-23.7% not sig
different via paired t-test from
OP proportional increase
28.2+/-23.8%
V difference in TF b/w arms by
BIS (mL) & OP: r = 0.88
V difference in ECF b/w arms
by BIS (mL) & OP:
r = 0.90
V difference in ICF b/w arms
by BIS (mL) & OP: r = 0.80

CG =13: women no
history of lymphedema
or BC.
LG =23: women
clinically diagnosed
with unilateral arm
BCRL.
Resistivity
determination cohort
=66: data of women
drawn from a body
composition database
at the University of
Queensland
Exclusion:
Pacemaker, pregnant

BIS can quantify arm volume &
monitor increases in ECF;
Strong correlations b/w volume
measurements of BIS & OP;
Predicted V increased with
magnitude of difference (no
constant bias) due to positive
slopes of correlations;
Good agreement between
classification of lymphedema
BIS may be more appropriate in
measuring early stage
lymphedema b/c changes are
mostly in fluid V vs. OP which
considers overall volume
(including fat content)

Lacks accuracy of
BIS-derived
predictions of fluid
volumes; currently no
true accurate
quantification of ECF
Error using arm
length calculated as a
proportion of stature
rather than exact arm
length; DXA
measured whole arm
vs. OP measured
40cm from wrist
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Water Displacement compared to Circumferential Measurement
Study Design,
Level of
Evidence
Correlational
D2
Level IV

Author, Year

Study Objectives

Karges et al.,
(2003) PT

To establish a
concurrent validity
for WD volume &
girth measurements
(CMs)

Megens et al.,
(2001) APMR

To compare IER &
test-retest reliability
of WD volumetry
& CIs (single
TCCV a.k.a. FSM
& summed
truncated cone
calculation).

Correlational
D2
Level IV

Meijer et al.,
(2010) (L)

Compare 4 cm
interval CM & 8 cm
interval CM to WD
Compare the
intrarater &
interrater reliability
of the above
physical
measurements

Association
D2
Level IV
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Assessments

Psychometrics

Population, Setting

WD volume
Minus fingers (UEF) WD volume
CM (girth
measurements)

Reliability when assessments of
UE volume compared:
CM to WD volume
ICC: 0.99
Coefficient of determination:
0.98
t = -7.58
CM to UE-F
ICC: 0.99
Coefficient of determination:
0.98
t =-3.88
WD Volumetry:
ICC: 0.99
CMs:
ICC: 0.99
Concurrent validity for WD
volumetry & FSM
m difference is -47ml
SD: 164 ml
r = 0.94
Concurrent validity b/w
volumetry & truncated cone
calculation
m: -137ml
SD: 118 ml; r = 0.97
1st Measurer: WD
measurement:
Compared to 4 cm CM: p =
0.54, ICC: 0.87
Compared to 8 cm CM: p =
0.01, ICC: 0.71
4 cm CM compared to 8 CM: p
= 0.00 cm, ICC: 0.8
IAR:
WD-Affected arm: p = 0.07,
ICC: 0.98 Unaffected arm: p =
0.16, ICC: 0.95

14 F w/ a diagnosis of
UE LE & receiving tx
from a specific
women’s health clinic:
convenience sample.
Range: 44-71 y.o
BC related LE: 13
Traumatic Accident: 1

There was a high association
b/w CM & WD values. Though
both valid assessments of LE,
one measurement cannot be
replaced w/ the other during
treatment because the resulting
values varied b/w WD & CM.

Small study from one
clinic, so
generalizability is
limited. LE resulting
from different
sources (traumatic
accident rather than
side effect of BC tx)

25 F who had lymph
node removal as part
of tx for unilateral BC
Age range:35-67 y.o
subjects recruited from
two sources, but 3
subjects’ data were
excluded because they
had bilateral LE.

Pearson’s R indicates good
correlation b/w WD volumetry
& both types of CMs. Limits of
agreement value, suggests that
CMs provide high values for
arm volume.

This was a small
study w/ patients
receiving different tx.
Only one of the PTs
took measurements
the 2nd visit, which
could impact
reliability of reported
measures.

30 F volunteers w/ LE
as a complication of
BCT
R arm affected: 18
L arm affected: 12
Age mean: 56.4
Age range: Not
provided

No sig. difference between
measurements of WD & 4 cm
CM
Sig. difference between
measurements of:
WD & 8 cm CM
4 cm CM & 8cm CM
IAR of WD, 4 cm CM, 8 cm
CM: no sig. difference
IER of WD, 4 cm CM, 8 cm
CM: no sig. difference
The above indicates that results

Not specified how
volunteers were
recruited. The results
from only two people
measuring were
compared. Not
specified if people
measuring knew if
participants had LE
or not. The 2nd
measurer’s ICC for 8
cm CM was very

WD volumetry
CMs to calculate
volume:
FSM & summed
truncated cone
calculation

4 cm interval CM
8 cm interval CM
WD

Summary of Results

Limitations
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Sander et al.,
(2002) PT

1.Determine the
IER & IAR of
upper extremity
(UE) volume
measurements from
WD & CM
methods
2.Determine the
relationship b/w

Correlational
D2
Level IV
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WD & CM

4 cm CM-Affected arm: p =
0.35, ICC: 0.99 Unaffected arm:
p = 0.47, ICC: 0.96
8 cm CM-Affected arm: p =
0.53, ICC: 0.99 Unaffected arm:
p = 0.62. ICC: 0.91
2nd Measurer: WD
measurement:
Compared to 4 cm CM: p =
0.68, ICC: 0.86
Compared to 8 cm CM: p =
0.00, ICC: 0.8
4 cm CM compared to 8 CM: p
= 0.00, ICC: 0.92
IAR:
WD-Affected arm: p = 0.77,
ICC: 0.97 Unaffected arm: p =
0.36. ICC: 0.96
4 cm CM-Affected arm: p =
0.77, ICC: 0.96 Unaffected arm:
p = 0.38, ICC: 0.9
8 cm CM-Affected arm: p = 0.4,
ICC: 0.92 Unaffected arm: p =
0.2, ICC: 0.62
IER between measurers:
WD-Affected arm: p = 0.30,
ICC: 0.91 Unaffected arm: p =
0.17, ICC: 0.92
4 cm CM-Affected arm: p =
0.37, ICC: 0.88 Unaffected arm:
p = 0.71, ICC: 0.85
8 cm CM-Affected arm: p =
0.54, ICC: 0.73 Unaffected arm:
p = 0.67, ICC: 0.72
Preliminary power analysis
(power = 0.80, effect size =
0.35) determined sample size
ANOVA & ICC used to
determine IER & IAR
reliability, Linear correlations
used to establish relationship
b/w WD & CM. LAA was used
to determine if WD & CM are

50 Fs, 25-85 y.o
recruited from Y-Me
Support groups &
from PT clinics in
Chicago area.
All participants had
primary or secondary
LE

of WD & 4 cm CM are more
similar to each other than results
of 8 cm CM is to either of the
other two measurements. 8 cm
CM has acceptable IAR & IER
as do WD & 4 cm CM.
Measures should not be
switched w/ each other for an
individual patient because of the
SD size of all measures.

low.

Found high IER & IAR for both
WD & CM.
Correlation b/w WD & CM was
strong, indicating a strong
relationship b/w the two.
Too much variability for the
methods to be interchangeable

Lack of blinding
second examiner
which could have
contributed to the
high reliability
ratings
Lack of diagnosis
information on
patients which may
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WD & CM
methods
3.Determine
whether WD or CM
measurements are
interchangeable.

Taylor et al.,
(2006) PT

To determine
reliability &
validity of how two
different methods
of CM compare to
WD

interchangeable. SEM
calculated for all measurements.

make more difficult
to generalize data

Arm Data: IER for WD &
CM.99, IAR for WD & CM .99
Range of LAA from 479 to 655
mL, range from this % was 1519%.
Hand Data: Range of ICCs for
IER from .91 to .98. IAR ICCs
ranged from .92 to .99. LAA
ranged from 108 – 152. , range
from this % was 18 – 24%.

Cross-sectional
comparison
D2
Level IV
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CM: distance from
fingertips to upper
boundary (30 to
60cm in 10 cm
increments)
CMAL: calculated
from 4 anatomical
landmarks
WD

Both arms measured 2x by 2
raters & calculated ICC via
ANOVA
CM IER all groups L & R arm:
0.98 to 0.99
CMAL IER all groups L & R
arm: 0.97 to 0.99
BC LG
ICC: IER
CM: 0.99
CMAL: 0.99
WD: 0.97
CG non-dominant arm: ICC
IER
CM: 0.98
WD: 0.94
Pearson coefficient r=0.98 b/w
CM & WD
LAA R arm:
CM (overestimated WD by 5%)
CMAL (overestimated WD by
5%)
R&L SEM CMAL: 64.565.4mL vs. SEM CM: 66.671.0mL

N=66 women recruited
from Breast Centre
and the Lymphedema
Clinic at Westmead
Hospital in Sydney,
Australia
CG: 25
BCG w/out arm
lymphedema: 22
BCG w/arm
lymphedema: 19

High IER of CM methods &
WD
CMAL higher validity than CM
due to smaller SEM relative to
WD
CMAL more accurate b/c lower
LAA w/ WD
LAA: CM & WD should not be
used interchangeably but can be
used individually
CM methods more efficient than
WD

Upper boundary of
WD 65% of distance
from elbow
olecranon to
acromion
Inclusion/ exclusion
criteria not detail
specified
Bias: Assumes WD
has higher validity
due to belief that arm
segments are ellipses
not truncated cones,
hence surface
irregularities not
captured; thickness of
measure in tape
interferes with
measurement
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Tewari et al.
(2008) AJS

To establish
accuracy &
compare WD
measurements w/
truncated cone CM
using wide &
narrow tape

Correlational
D2
Level IV

Cost-Related Study: Bilir et al, 2012
Study Design,
Author, Year
Study Objectives
Level of
Evidence
Bilir et al.,
To compare
Historical
(2012) AJMC
combined
D3
tx/assessment cost
Level V
over 1 year as
determined by
either BIS or CS
assessments
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WD & CM
(truncated cone)

CM UE Volume Estimation
Range narrow measuring tape:
1021.33-3775.05 ml
Range wide measuring tape:
1015.28-4125.56 ml
r = 0.95
WD UE Measurement
Range: 1075-3790 ml
Comparisons:
CM (narrow tape) to WD
r = 0.92 (CI: 0.89-0.94)
CM (wide tape) to WD
r = 0.88 (CI: 0.84-0.91)
Using BMI: CM to WD
Narrow measuring tape:
BMI: r = 0.792-r = 0.94
Wide measuring tape:
BMI: r = 0.70- r = 0.93

98 F volunteered
11 were excluded
87 F participated
M: 58.6 y.o
Range: 17-81 y.o

The results of the CM
measurements are almost
equivalent to the measures
obtained w/ WD. Narrow tape
measurement correlates slightly
better w/ WD than wide tape.
Measuring tape has the
advantages of no size/length
limit for use, is more portable, &
can be used on patients w/
wounds. CMs did result in
higher measurements than WD.

Participants were
excluded because
they could not use the
water tank. A larger
tank was not
provided to
accommodate these
individuals, thus the
study had a limited
size for the limb &/or
LE. Study was a
convenience sample,
so it will have low
generalizability.

Assessments

Psychometrics

Population, Setting

Summary of Results

Limitations

BIS: Pt is assessed
at every follow-up
visit w/ BIS
CS: Pt must selfreport symptoms to
then be assessed.
The two prevalent
methods in use are
circumferential UE
& WD

Base-Case Analysis:
Savings of $315,711.00 when
BIS assessment is used instead
of CS
Univariate sensitivity
analyses:
Single parameters changed to
investigate savings when BIS is
used instead of CS.
Scenario Analyses:
Compression sleeve:
Removing sleeve from CS
scenarios & adding custom
sleeves to BIS yielded savings
of approximately $5,000.00
Pneumatic Pump Use:
If pumps are removed from
model BIS savings are
approximately: $136,000.00

A hypothetical at-risk
population was
determined from a
hypothetical
population of 1 million
w/ insurance coverage.
The result was 627
patients.
Parameters used in
determining at-risk
population were as
follows: F, age>18,
patients diagnosed w/
BC/year

The base-case analysis indicated
that when BIS assessment is
used $315,711.00 per year is
saved when compared to CS.
Only in the most positive
scenario of the extreme value
multivariate analyses (the
scenario in which every outcome
for the patients is the minimal
cost) is BIS less cost effective
than CS. In the most negative
scenario annual cost of patients
receiving CS is $3,049,779.00 &
BIS is $1,422,250.00. In the
most positive it is $1,300,702.00
& 1,627,528.00 for CS & BIS
respectively. Early detection
cited as a reason for the
healthcare savings incurred by

There is little
longitudinal data on
LE.
Variability of
characteristics is
limited by a
population model
created w/ averages.
No non-cost benefits
or challenges were
explored w/ BIS or
CS.
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Higher Tx Costs for BISDetected Cases:
When 25% of cases require
CDT, BIS still yields a savings
of approximately $126,000.00
Low-/High-risk Populations
Only:
BIS yields savings of
approximately, $150,000.00
Infections:
Low infection projection yields
approximately $400,000.00 in
savings

BIS. This supports the use of
BIS assessments as a cost saving
component of identification & tx
of LE.

Recommended articles from Impedimed (Added on April 18, 2017)
Author,
Year

Study Objectives

Study Design,
Level of
Evidence

Methods &
Outcome Measures

Population/Setting

Summary of Results

Limitations

Laidley &
Anglin
(2016)

To assess role of
BIS in clinical
practice to detect
& monitor
subclinical LE

Case-Controlled
Retrospective
Study
O3
Level II

Patient Charts
reviewed from
Nov.2008-July2013;
Pts. Monitored
preoperatively;
assessed every
3months within 2 y.
post-surgery; L-dex
U400 used for
measurement

326 women: breast cancer patients
from two surgical practices
M: 56.2 y.o
210 women: SLNB
116 women: ALND

286 women: normal L-Dex score
Subclinical BCRL incidence: 12.3% (40 women)
w/rate of 4.3% for SLNB & 26.7% for ANLD
SLNB: mean time to positive LE assessmen via LDext: 5.6 months from preoperative assessment &
mean follow-up from subclinical BCRL diagnosis
15.7 months.
ALND: mean time to positive LE assessment: 7.5
months from preoperative assessment & mean
follow-up from subclinical BCRL diagnosis 13.4
months.

Retrospective review
limits validation of
these findings;
limited information
available in charts
Unable to evaluate
other factors (BMI &
radiation) that
contributed to
increase risk in LE
Reasons why LE tx
began could not be
determined due to
clinician discretion

Soran et al.
(2014)

To detect and
compare incidence
of subclinical LE
between patients
prospectively
monitored by BIS

Controlled
Clinical Trials
(prospective
cohort study) E3
Level II

BIS via L-Dex U400
CM via tape
measurements
Divided into 3
groups:
Pre-op group: newly

180 participants w/breast cancer
enrolled in the Maggee-Women’s
Hospital Breast Cancer Center LE
Education, Monitoring, Early
Detection, and Prevention Program
prospective database.

Incidence of clinical LE in CG: 36.4% at 12 month
follow up; sig. higher than pre-op group: 2.8%
incidence of clinical LE in 19 month follow-up
No pre-op & pre-op group incidence of clinical LE:
4.4% (20 month follow-up)
Subclinical LE diagnosed in 28 patients in the pre-op

Small sample size;
not generalizable;
considers only
ALND

LYMPHEDEMA ASSESSMENTS

26

& patients
assessed via CM.

LYMPHEDEMA ASSESSMENTS

diagnosed patients
w/baseline L-Dex
measurements prior
to surgery and
monitored via L-Dex
No Pre-op group:
Patients showed no
signs of clinical LE
via CM and initial
BIS reading was 6
months post surgery.
CG: patients who had
preoperative Baseline
L-Dex measurements
but monitored w/ CM
due to lack of
insurance coverage.
Average follow-up
was 19 (preop),19(CG) , and 25
(post-op) months

group and 17 patients in the no pre-op group
Reduction rate of clinical LE 32%95.6% of patients
diagnosed with sublinical LE via BIS did not
progress to clinical LE
33% of women monitored via L-Dex measurements
were diagnosed with subclinical LE and given early
intervention.
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GENERAL ABBREVIATIONS KEY:
A: Affected
ALND: Axillary Lymph Node Dissection
ANOVA: Analysis of Variance
AUC: Area under the curve
BC: Breast Cancer
BCG: Breast Cancer Group
BCRL: Breast cancer-related lymphedema
BCS: Breast cancer survivors
BCT: Breast Cancer Treatment
BIA: Bioimpedance Analysis
BIS: Bioimpedance Spectroscopy
B/w: Between
CAML: Circumferential Anatomical Landmarks
CC: Concordance Correlation
CG: Control Group
CI: Confidence Interval
CM: Circumferential Measurement
CS: Current Standard
DMM: Disk model method
DXA: Dual x-ray absorptiometry
ECW/ECF: Extracellular Water/Fluid
EDGE Task Force: Evaluation Database to Guide
Effectiveness
EIS: Electrical Impedance Spectrograph
F: Female
FSM: Frustum sign method
hx: history
I: Intervention
IAR: Intra-rater reliability
IER: Inter-rater reliability
ICC: Intraclass correlation coefficients
ICF/W: Intracellular Fluid/Water
IOV: Infrared optoelectronic volumetry
LAA: Limits of Agreement Analysis
LCC: Lin’s Concordance Correlation
LE: Lymphedema
LG: Lymphedema group
LOA: Limits of agreement
LV: Limb Volume
LYM: Lymphometer
M: Mean
MDC: Minimal Detectable Change
MCID: Minimal Clinically Important Difference
MFBIA: Multiple Frequency Bioimpedance Analysis
OM: Outcome Measure
OP: Optoelectronic perometry
OT: Occupational Therapist
PT: Physical Therapist
RD: Relative Differences
R&L: Right and Left SD:
Standard deviation
SEM: Standard Error of Measurement
SFBIA: Single Frequency Bioimpedance Analysis
LYMPHEDEMA ASSESSMENTS

Sig: Significance
SLNB: Sentinel Lymph Node Biopsy
SLN: Sentinel Lymph Node Dissection
TF: Total fluid
TDC: Tissue Dielectric Constant
w/: with
Tx: Treatment
U: unaffected
WD: Water Displacement
WV: Water Volumetry
y.o: Years old
JOURNAL ABBREVIATIONS KEY:
AJMC: American Journal of Managed Care
AJS: ANZ Journal of Surgery
AO: Acta Oncologica
APMR: Archives of Physical Medicine &
Rehabilitation
APS: Annals of Plastic Surgery
ASWC: Advances in Skin and Wound Care
BCRT: Breast Cancer Research & Treatment
CI: Cancer Investigation
JSO: Journal of Surgical Oncology
(L): Lymphology
LRB: Lymphatic Research & Biology
PT: Physical Therapy
RO: Rehabilitation Oncology
SCC: Support Care Cancer
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Summary of Key Findings:
Summary of Outcome Studies
Circumferential measurements (CM), water displacement (WD), and bioimpedance (BIS) are highly recommended due to
their reliable and valid psychometric properties and clinical utility (Perdomo et al., 2014). BIS is an effective tool for di agnosis
of well-established BCRL (Seward et al., 2016). Shah et al. (2013) and Bundred et al. (2015), a descriptive study, found BIS to
be valid in detecting early onset lymphedema post-surgery, however, Seward et al. (2016), found that there is not enough
evidence to conclude that BIS detects breast cancer related lymphedema earlier than other measurement techniques.
Additionally, BIS was found to effectively monitor lymphedema from baseline to post-surgery via tracking reductions in LDex scores (Shah et al., 2013). Presumably CM cannot differentiate between intracellular fluid and extracellular fluid because
measurements are taken externally. Evidence suggests that BIS can make a distinction intra - and extracellular fluid
accumulation (Shah, 2013). When compared to other measurement methods, BIS is more reproducible (Adriasenssens et al.,
2013; Cornish et al., 1996), time efficient, sensitive, quantifiable, portable and easier to operate (Ward et al., 2006).
Additionally, BIS was found to be better accepted by clinicians, therapists, and patients (Ward et al., 2006). BIS quantified
significant differences between dominant and non-dominant limbs (Fu et al., 2012; Ward, 2006). Soran et al. (2014) found that
participants assessed via BIS to monitor lymphedema had significant lower incidence rates of clinical lymphedema compared
to participants assessed via CM. Similarly, Laidley and Anglin (2016), demonstrated that BIS identified patients in need of
BCRL treatment when incorporated early into routine clinical practice and used as part of routi ne follow-up, resulting in
reduced chronic clinical BCRL. The consistency of these outcome findings suggest that BIS may be the most suitable
assessment to use when evaluating lymphedema.
Summary of Descriptive Studies
The literature described a variety of methods and comparisons among lymphedema assessments. WD and CM, regarded as
the former gold standards to measure lymphedema, were commonly compared in the research. Deltombe et al. (2007) found
that frustum sign method calculations had higher reliability compared to disk model method calculations of CM.
Additionally, Taylor et al. (2006) found that CM of anatomical landmarks was more reliable and valid than CM (wrist to
axilla) due to its smaller SEM when compared to WD. CM and perometry (OP) demonstrated high inter-rater reliability and
intra-rater reliability when compared to WD (Deltombe et al., 2007). Results from Karges et al. (2003) also support
physical measurements having a high correlation with each other using WD and two types of CM. Truncated cone
measurements were shown to underestimate volume compared to OP (Czerniec et al., 2010). Meijer et al. (2004) found high
correlation between 4 cm interval CM and WD, but not 8 cm interval CM and WD. Megens et al. (20 01) found similar
correlation results with the same physical measurements as Karges et al. (2003). The strong relationships found between
WD and CM provided a comparison in the literature to assist in determining the psychometric properties of
OP and BIS. According to Czerniec et al. (2010) BIS showed slightly higher interrater reliability when compared to
truncated cone measurements. While BIS was shown to be the more favorable option in most studies, it may not be as
accurate in other populations, particularly in individuals with bilateral lymphedema (Warren et al., 2007).
The research showed BIS and OP to be valid measurements of lymphedema. According to Moseley, Piller and Carati
(2002), BIS was a more accurate assessment of limb fluid change while OP provided an accurate determination of total
limb volume change. Both were equally valid in measuring leg volume changes and were non -invasive and quick methods
to assess secondary lymphedema. OP, water volumetric, and CM also have high intra-rater reliability (Hidding et al., 2016;
Jain et al., 2010). Both Ward et al. (2009a,b) studies demonstrated that BIS and OP were strongly correlated. In contrast,
Bundred et al. (2015) found moderate correlations between BIS and OP, concluding that BIS may be a suitable alternative
to OP in detecting lymphedema.
Ward et al. (2009a) found good limits of agreement when classifying lymphedema, however BIS and OP demonstrated
relatively poor limits of agreement due to having different units of measurement; hence these methods cannot be used
interchangeably but can be used independently. The inability to interchange methods of measurement was supported by
Bilir et al. (2012), Czerniec et al. (2010), Czerniec et al. (2009), Karges et al. (2003), Megens et al. (2001), Meijer et al.
(2004), Moseley et al. (2002), Perdomo et al. (2014), Sander et al. (2002), Ward et al. (2009a, b) and Warren et al. (2007).
Similarly, Ridner et al. (2007) and Mayrovitz et al. (2000) both found strong correlations between CM and OP and
moderate correlations between CM and BIS methods. From the correlations found in this study, they concluded that each
assessment was valid in measuring upper limb lymphedema. Adriasenssens et al. (2013) found OP to be beneficial because
it has reproducibility, ease of use, and the results of its volume estimates were between WD and CM. Ward et al. (2009a)
noted that a limitation of OP in their study was its inability to detect lymphedema close to axilla, indicating lower validity
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in these results. According to Ward et al. (2009b) BIS quantifies upper limb volume and detects changes in limb volume.
Similarly, Czerniec et al. (2009) found that BIS detected localized changes with a higher degree of sensitivity than total
limb volume measures because BIS has the ability to differentiate between ECF and other fluids. Therefore, they concluded
that BIS could detect localized lymphedema more readily than OP (Czerniec, et al., 2009).
An overall finding in Czerniec et al. (2010) was that physical measurements (truncated cones, perometer, BIS) are
correlated with each other. Bilir et al. (2012) concluded that in all but the most ideal situation, BIS is a more cost -effective
method of measurement for lymphedema when compared to standard methods. BIS is also the ideal measurement for early
stages of lymphedema and is also effective for later stages (Bundred et al., 2015). Although we found a variety of studies on
lymphedema assessments, their results and conclusions were similar in suggesting that BIS may be the most suitable
assessment in comparison to CM, WD and OP to use for the evaluation of lymphedema.
Implications for Hospital/Clinic Purchaser of assessment products:
This critical appraisal will provide hospital and clinic purchasers with informative research regarding the comparisons of BI S,
OP, and CM. Our analysis of the literature will potentially impact the decisi on-making of purchasers who may need to
consider assessments most suitable for their setting, population, and budget. The evidence demonstrated that BIS was
preferred under many conditions (Perdomo et al., 2014; Seward et al., 2016; Warren et al., 2007). B ilir et al. (2012) proposed
that using BIS was the most cost effective method due to its high sensitivity in detecting and monitoring lymphedema. A
barrier to using BIS in clinical practice may be cost and lack of insurance coverage, resulting in using CM which is not as
effective as detecting subclinical lymphedema (Soran et al., 2014). Additionally, BIS was found to have strong correlations
with previous gold standards such as CM and WD (Czerniec, 2010; Fu et al., 2012; Ridner et al., 2007). was found to be more
time-efficient (Ridner et al., 2007; Ward, 2006), valid (Ward et al., 2009a) and reliable (Hidding et al., 2016; Jain et al., 2010 )
when compared to CM and OP. Fu et al. (2012) found that BIS was time-efficient when compared to CM. Although OP and
BIS were strongly correlated in the literature, OP demonstrated less sensitivity and accuracy in measuring change in ECF
(Czerniec et al., 2010; Moseley et al., 2002). Overall these findings will allow purchasers to present this information to
insurance companies and other sources of reimbursement, in order to facilitate coverage for the costs of BIS.
Implications for Consumers (Patient):
Based on the literature examined, BIS appears to be a more sensitive (Bilir et al., 2012; Bundred et al., 2015; Sha h et al., 2013)
and time-efficient (Fu et al., 2012; Ridner et al., 2007; Ward, 2006) assessment of lymphedema in comparison to CM and OP .
As a patient it is imperative to self-advocate for baseline lymphedema measurements prior to undergoing surgery. Evi dence
shows that this will aid in earlier detection of lymphedema. When considering assessment options, BIS would be the preferred
assessment to measure preoperative baselines because its high sensitivity allows for earlier detection of lymphedema (Bundred
et al., 2015; Shah et al., 2013). BIS has the ability to carefully monitor LE, diagnose subclinical LE, and initiate early
intervention, thus reducing the incidence rates of clinical lymphedema (Soran et al., 2014). Early diagnosis of lymphedema vi a
BIS has shown potential to lead to a better prognosis because treatment can be started sooner rather than later, resulting in
overall lower total treatment costs (Bilir et al., 2012). Additionally, evidence shows that treatment of lymphedema implement ed
earlier may prevent chronic lymphedema (Bundred et al., 2015; Laidley and Anglin, 2016).
BIS also takes less time (5-6min) to administer which provides ease of scheduling for consumers (Ridner et al., 2007). Overall,
this critical appraisal gives an extensive synthesis for any consumer who desires to be well-informed about his/her treatment
options.
Implications for Practitioners:
This information will allow lymphedema specialists (OTs & PTs) to be more certain that they are using valid and reliable
assessments in order to provide optimal care for their clients with lymphedema of the limbs. They should use this critical
appraisal as a supplement to their clinical reasoning to select an assessment that is in the best interests of their clientele. If
clinicians make use of this critical appraisal, their sessions will focus more on treating lymphedema and meeting client
needs rather than spending a majority of the time assessing lymphedema. Clients rely on clinicians for the best care
possible and many times, rehabilitation directors are unaware of what is best for clients because they do not work directly
with them. Clinicians have the duty to aid in the development of programs that adopt instruments such as BIS in their
clinics and they also play a primary role in providing this information to supervisors and directors who can then work
toward insurance coverage and reimbursement. The literature supports that clinicians could be confident in implement ing
BIS into practice due to its concurrent validity with other lymphedema assessments available on the market (Jain et al.,
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2010). Additionally the research found that BIS was reliable (Jain et al., 2010), valid for early detection (Shah et al., 201 3),
valid in measuring leg volume changes (Moseley et al., 2002), time-efficient (Fu et al., 2012; Ridner et al., 2007; Ward,
2006), economically beneficial (Bilir et al., 2012), client-preferred (Ward, 2006), and user-friendly (Fu et al., 2012) when
compared to other lymphedema assessments.
Implications for Researchers:
A majority of our studies noted that lymphedema is not well defined, which makes it difficult to compare among studies. Also,
in most cases, the research that utilized control groups was not blinded (Hidding et al, 2012), however, in an example when
blinding was partially utilized, there was potential for inaccurate reliability results (Sander et al., 2002). It might be imp ortant
for researchers to establish normative ranges for individuals based on height, weight, and other integral characteristics. B IS
currently measures unilateral lymphedema and is not as accurate for bilateral lymphedema (Warren et al., 2007). Normative
values may also provide a comparison that would allow BIS to measure bilateral lymphedema (Dylke et al., 2016; Ward 2006).
BIS measures cannot be compared to other measures without being converted; this implies a need for a standardized equation
that can be used across all settings (Ward, 2006; Ward et al., 2009b). Researchers should be aware of these weaknesses that
exist because of the nature of assessing lymphedema.
Implications for Evidence Researchers:
Evidence regarding early detection and diagnosis was not searched for systematically, but was included in some research that
addressed measurements. In the scope of evidence we examined, BIS was most effective at detecting lymphedema because it is
a more sensitive measure than CM, WD, and OP (Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al., 2009; Hidding et al .,
2016). Self-report was also not a focus of our research, but was used in five articles we found (Bilir et al., 2012; Czerniec et al.,
2010; Hidding et al., 2016; Perdomo et al., 2014; Ridner et al., 2007). Czerniec et al. (2010) suggests that BIS and self -report
are both sensitive to small changes. Robotic 3D scanning is another form of lymphedema measurement that was seen during our
searches. It is a new technology that may be effective in lymphedema measurement. Future research should be conducted on
early detection and diagnosis of lymphedema as well as self-report and robotic measurements. For further information
pertaining to early diagnosis or robotic 3D scanning, please refer to the bottom of the reference list.
Bottom Line for Occupational Therapy Practice/ Recommendations for Better Practice:
Occupational therapy practitioners who specialize in lymphedema need to understand that CM and WD used to be
considered the ‘gold standard’ for measuring lymphedema. Unfortunately, these measures do not take into account other
non-lymph types of edema. BIS has the capacity to discriminate between differing fluids within the limbs (Czerniec et al.,
2009). Other benefits to BIS include its portability, ease of use, time efficiency, reproducib ility and quantifiability (Ward et
al., 2006). In addition to discriminating between types of lymphedema, BIS also has the ability to detect lymphedema
earlier than other assessment methods due to its level of sensitivity (Bilir et al., 2012; Czerniec et a l., 2010; Czerniec et al.
2009; Hidding et al., 2016). Early detection generally leads to earlier treatment and ultimately lower long -term cost and
better outcomes for patients (Bilir et al., 2012; Bundred et al., 2015). Early detection could be a key fact or in determining
between acute and chronic lymphedema, which is important for OTs to consider (Bundred et al., 2015). Occupational
therapy practitioners must use discretion and decide if implementation of these measurement tools are integral to the ethics
of their practice and the needs of their client population.
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Involvement Plan
After meeting with Shaffer and discussing our comparisons of CM, BIS, and perometry we decided to
translate our findings by providing an in-service presentation to her lymphedema team and other MultiCare
employees. Shaffer would like us to focus primarily on the two assessments she uses in practice: CM and BIS, and
give a brief overview of perometry. The purpose of our presentation is to inform her colleagues about the benefits of
using BIS to assess unilateral lymphedema from both a patient and practitioner perspective.
Shaffer is a pragmatic user of the L-Dex (a BIS device) because of its easy administration, reliability, time
efficiency, and cost effectiveness. However, due to Medicare and other federally funded insurance companies
providing limited to no coverage, she is unable to utilize the L-Dex for many of her patients. We have been
corresponding with Impedimed, the creators of the L-Dex, and according to their insurance representative,
Washington is located in the Noridian Medicare region, which does not provide consistent coverage of the L -Dex or
any BIS measure. Therefore, Shaffer would like us to include this piece of information in our presentation and offer
potential solutions to encourage our regional Medicare administrative contractor (MAC) to initiate coverage.
We plan to gather in-service outcome data by distributing a survey to our audience to measure what
information they gained from our presented research and ideas they have to advocate for insurance coverage of the
L-Dex. Additionally, Shaffer requested we develop a brochure she can provide to inform her patients about t he
benefits of using CM and BIS how these assessments may impact lymphedema treatment. Shaffer requested that
brochure be simple, easy to read, but informative in order to avoid confusing any of her clients.
ARC: Availability, Responsiveness, Continuity
The knowledge translation of the research found and characteristics of Shaffer and MultiCare apply best to
the ARC model: Availability, Responsiveness and Continuity. Although MultiCare currently uses the L -Dex, the
issue with federal insurance not providing coverage for BIS is a complex social context that may impact the
effectiveness of our research.
Availability
The ability to diffuse the information we have compiled to the largest group of people possible in order to
see long term effect may be seen as a barrier. The audience receiving the data limits how far it may be able to be
spread. At this time, the information we are trying to convey is limited to the therapists and staff of MultiCare.
LYMPHEDEMA ASSESSMENTS

32

Another factor that presents a possible barrier is that BIS is not currently covered by Medicare, which is the insurer
of a majority of MultiCare patients. On the other hand, it could be considered a facilitator that several of the private
insurance companies are currently reimbursing for BIS measurements now and Medicare may follow the trend at
some point in time. Shaffer mentioned that MultiCare as an entity may be willing to complete a research study in
order to collect the data needed to persuade the Medicare representative for our region into acce pting BIS
measurements as valid and reimbursable by Medicare. Unfortunately, research calls for more random control trials
that are longitudinal and follow patients throughout the entire process of detection and treatment in order to provide
proof of an overall cost reduction. This process would take several years which could be considered a barrier as
well.
Responsiveness
One factor that may be a barrier or a facilitator is how the information that we present to MultiCare is
received. People may choose to accept or reject the data presented on an individual basis. Additionally, anyone who
receives the information, including individual therapists, managers, department heads, etc., also has a choice as to
what they will do with the information once it is received. If those who receive the information feel that action needs
to be taken, so that they can continue to use BIS without taking a financial loss, how they implement that change
may be limited to the power structure and decision making process that MultiCare has in place. Great intentions are
not generally enough to make long term change. Hard work and perseverance are usually required and those who try
to implement change may either be met with support or be presented with barriers to their attempts.
Continuity
This knowledge has the potential to make a long-term change if it plays a part in Medicare accepting BIS as
a reimbursable measurement tool for lymphedema. This would be a huge facilitator to long term continuity,
however, the time it would take to achieve this goal is unknown. Currently, a large number of the lymphedema
therapists at MultiCare are already using BIS to measure lymphedema in their patients, therefore, accepting and
implementing this into practice over a long period of time consistently should not be difficult to do. It may be
considered a barrier for MultiCare to have to train anyone who is not already using BIS due to the financial cost and
time that it may take. On a broader scale, it may be a long-term barrier for patients to utilize BIS due to insurance
companies not providing coverage.
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An outline of the scheduled dates for the completion of these tasks/products
Task/Product

Deadline

(1a-f above)

Date

Steps w/ Dates to achieve the final outcome

Completion
Date

Presentation
and Outcome
Survey

04/14/2017

Shaffer is working towards setting up a quarterly meeting prior to
the deadline for our final paper (sometime in April). There is no set
date for this meeting yet, but we plan to complete our presentation
by or before March 30, 2017 in order to be fully prepared for
whenever this meeting might occur. Cullyn will be in charge of
developing questions for the outcome survey and will assign tasks
to the group as needed. Divina will be in charge our PowerPoint
presentation and will also assign tasks to the group as needed.

3/26/17

Brochure for
Patients

04/14/2017

This brochure will be completed prior to our presentation (April
2017) with Shaffer and colleagues. This will be helpful to be able
to distribute to multiple therapists at once. We will begin working
on this brochure immediately (February 22, 2017). Connie will be
in charge of completing the brochure and will assign tasks to the
group as needed.

3/20/17

Poster
Presentation

05/03/2017

The printing of this poster will be completed on Monday, May 1,
2017. We will begin work on this poster April 1, 2017, and will
complete the poster 3 days following our presentation with Shaffer
and her colleagues. Jessica will be in charge of completing the
poster presentation and will assign tasks to the group as needed.

Time lapse
video demo

04/2017

This time lapse will need to be conducted at Shaffer’s office with a
client, so that we can demonstrate the difference in time efficiency
between the L-Dex and CM to those at the poster presentation;
sometime in March or April.

4/30/17

We will evaluate the outcome of all of these projects and the information shared from the research we have
conducted through administration of the outcome survey to all lymphedema therapists present at the quarterly
meeting in April, 2017. We also plan to meet with Shaffer following that presentation to debrief and reflect upon the
effectiveness of the presentation and what steps need to be taken for following research groups (conference call). In
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addition to these steps we would like to meet with our chair (George Tomlin) to ensure we have adequately
distributed the information we gained from our research.
Activities and Products Completed
Brochure for MultiCare Clients (Appendix A)
The intention of the brochure was to create a product for the consumer that would clearly
inform them of the choices available to them for lymphedema assessment and the advantages and possible
disadvantages of each. Providing consumers with opportunities to make informed decisions related to their health
care is empowering and increases health literacy. Through our research and conversations with Heidi Shaffer, it was
determined that CM and BIS, via L-Dex, were the two assessments utilized by MultiCare lymphedema specialists.
Within the brochure, we provide basic information about the two different assessments which include a definition of
both assessments, their pros and cons, why it is important for them to have this information, and additional
resources.
Currently, the CM technique is bundled into the evaluation billing code for lymphedema assessment and is
typically reimbursed by insurance. Unfortunately, BIS is a fairly new assessment technique, and as such, is only
sporadically reimbursed by insurance. MultiCare physicians have stated that they prefer to use BIS the majority of
the time. With reimbursement being at the discretion of insurance companies, there is a possibility that there will be
a cost to the consumer for this assessment method if used. MultiCare has lowered this cost as mu ch as possible and
essentially only requires the consumer to cover the cost of supplies at $70. This is a large part of why MultiCare
wanted a brochure created. The consumer has to agree to cover this cost (if not reimbursed by insurance) and they
are more likely to do so if they clearly understand the advantages of BIS.
Creating the brochure was fairly straightforward and simple. Determining what needed to be included
required conversation between Shaffer and our group which was not difficult, but time con suming. Edits were
decided upon as a group and the final product was completed using Microsoft Publisher software. In addition, we
created an outcome measure for the therapists to track the brochure’s usefulness. Suggested outcomes questions
were also provided with the brochure that Shaffer and her team could use to gather data on the knowledge
translation to clients via the brochure.
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In-service Presentation for MultiCare Staff (Appendix B)
Upon meeting with Shaffer, after completing the research she had requested, we were able to confirm that
BIS was the preferred assessment measurement. Due to the fact that the majority of therapists at her clinic, including
herself, already utilize BIS and understand the benefits, our research provided empirical evidence to confirm what
her and her colleagues already believed to be true. The insurance coverage issues identified throughout the research
became an additional focus area of this knowledge translation project. Shaffer felt that it would be most appropriate
for us to present information on what the staff can do with this new evidence and how they can be a part of the
bigger picture. This bigger picture, long term effect is that of convincing insurance companies, mostly Medicare,
that BIS is a reliable, valid, and safe assessment for diagnosing and measuring lymphedema. Along with measuring
lymphedema, BIS has been shown to be capable of early detection of lymphedema if used in the early stages of
treatment. Early detection has the potential to decrease incidence as well as total treatment time. There are several
ways that MultiCare can help to advocate for BIS to become a covered lymphedema assessment, as well as a tool to
be utilized for early detection, which were also discussed during the in-service.
Originally, Shaffer intended for us to present this information to all of therapists on staff at her MultiCare
location. Unfortunately, due to unavoidable scheduling conflicts, we were unable to attend and present at her
facility’s quarterly meeting. Shaffer stated that she preferred for us to present the information to Olsen, who
oversees all the MultiCare lymphedema specialists in this region.
Google slides software was utilized to compile the data and information needed to present all of the
findings and future implications of our research project. Acquiring the information needed in relation to insurance
coverage of BIS and early detection was a difficult, but rewarding process. We reached out to Impedimed, the
company that manufactures the L-Dex, to seek whatever knowledge they possessed on this topic. Many reciprocal
emails and phone calls led us to Fustgaard, who agreed to meet with us in person to discuss our research findings
and shared with us some of what their company is doing to advocate for insurance coverage of BIS. The meeting
with Fustgaard was very informative and in that process, we received some new research articles as well. Permission
to share what we had discussed with her in our presentation was given verbally and in written format . After meeting
with Fustgaard, we felt that we had the necessary data to complete our PowerPoint and schedule a time to present it
to Olsen of MultiCare. Olsen informed us of what collaborations MultiCare already have in the works to address this
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issue as well as what they do at the therapist level to contribute to the growing body of evidence related to this topic.
The results of the collaborations between Olsen and Fustgaard were informative for all parties involved. We had
Olsen and Fustgaard fill out a qualitative questionnaire in order to measure outcomes of the research findings.
Outcomes and Effectiveness
Statement of Outcomes (Appendix C)
We presented our findings and conclusions to three individuals Shaffer, Fustgaard; and Olsen in separate
meetings. We created a qualitative outcomes questionnaire for these three individuals to fill out after our individual
presentations for Fustgaard and Olsen. Our collaborating clinician filled out the survey after working with us
through the entire process.
In her response to our questionnaire, Shaffer reported that our research seemed to comprehensively explore
tools used to measure lymphedema. Before our presentation, she had not been aware that BIS measurements are
covered in other regions of the United States. In her response, Fustgaard expressed that she would like to collaborate
with “researchers…to approach regional clinics”. We received a separate email from Fustgaard on 04/25/2017
stating that she spoke with the Impedimed “head of clinical...about your paper, and we feel it’s a fair, balanced
review of the technology.” Olsen thanked us for providing “updated information and work [we] did to identify payer
information” on her questionnaire. She did not report either learning anything new from our presentation or would it
change how she advocates for coverage, but she felt we omitted no crucial information.
One of the products we created for our collaborating clinician was an informational brochure comparing
CM and BIS (the two assessments currently offered at Multicare). With the brochure, we included suggested
outcomes questions for Shaffer to use to collect data on the interest in and response to the brochure. Tracking how
many brochures are taken over the course of a three month, six month, and year period is a suggested outcome
measure in that document. We suggested the clinician inform staff of this tracking because they may be able to help.
Effectiveness of the client brochure
A client brochure comparing the two measurements (L-Dex and circumferential measurement) provided at
Shaffer’s lymphedema clinic was given to MultiCare for dissemination. The brochure provided pros and cons along
with education on how each measured lymphedema differently. Shaffer and her supervisor Olse n felt this
information would be beneficial to provide to their clients. This brochure is to be given to clients combined with
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therapist education. The effectiveness of the client brochure is beyond the scope of this endeavor, but the hope is
that it will better inform each client and include them more in the decision process as well.
Effectiveness of meeting with Impedimed
Over the duration of our project, we corresponded with Impedimed in order to learn more about the L-dex
and insurance coverage. On April 10, 2017 we met with Fustgaard to discuss our research findings, review the
content in our PowerPoint presentation, and gain more information regarding insurance covering BIS. The meeting
went very well and based on Fustgaard’s feedback we felt that our research findings had more meaning because of
its potential impact to benefit individuals with lymphedema. Fustgaard was very pleased with our research and
presentation. She also had many Impedimed employees review our slideshow presentation, including the CEO,
Richard Carreon who provided us with great constructive feedback. We had the opportunity to clarify and gain more
insight on Medicare coverage and ensure that the information we were sharing from Impedimed was accurate and
approved. Additionally, Fustgaard brought us great resources, including a recent study from 2016, which supports
the conclusions we drew from our critical appraisal of the literature. This article was added to our CA T table to
provide more evidence regarding effectiveness of BIS in clinical practice. Overall, meeting with Fustgaard was
effective for all of us because it gave us an opportunity to share our findings and put our research more into a
meaningful context. We gained perspective about how our critical appraisal has the potential to help make a
difference in individuals needing lymphedema measurements.
Effectiveness of Presentation to Sherri Olsen
The presentation to Olsen on April 14, 2017 went very well. She expressed that she was pleased with our
research findings, implications, and information regarding insurance coverage issues. She informed us that
MultiCare’s oncology department is planning to initiate research of their own regarding the L-Dex. Olsen asked if
we could send her our presentation and final paper to utilize for future reference. It was such a great experience to
convey our findings to someone who is in the position to utilize them and make a difference in patients with
lymphedema. Olsen confirmed that she currently is collaborating with Impedimed to discuss technological updates,
insurance, and further research opportunities. Additionally, she confirmed that she understands the ben efits of BIS
and is supportive of using the L-Dex in clinical practice. Olsen made us feel that our review of the literature was
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worthy and invaluable to those involved in lymphedema care. Overall, we felt that her response to our presentat ion
indicated that our research analysis was effective and meaningful.
Analysis of the Overall Process
In September 2016, we chose to work with Shaffer, who is an occupational therapist and lymphedema
specialist at MultiCare in Gig Harbor, WA. After meeting with her, we understood the focus of research she
expected us to explore. The question we collaboratively constructed was not convoluted, rather direct and simple,
which eliminated extensive research to first develop a research question. We were able to focus our time on finding
a comprehensive amount of research on the lymphedema measurements in the literature. This caused the beginning
of our process to be quite simple, but extensive. We felt inundated with a considerable number of articles to sift
through with terms related to lymphedema that were unfamiliar to us. This required additional exploration to
understand what several lymphedema terms meant and how they were implemented in practice. We watched videos,
sought guidance from Shaffer, and read many additional articles to increase our comprehension.
The factor that proved surprisingly difficult was ensuring that we had documented all the searches we had
made, all the articles we kept, and all the duplicates we found. As a group of four individuals, it proved even more
difficult to ensure organization in our searches in order to not duplicate searches or miss important search avenues.
Our chairperson along with our librarian liaison provided valuable insight to ensure higher likelihood for saturation
of articles in an organized manner. After firmly developing our inclusion and exclusion criteria, it became clearer as
to which articles we had to include and which must be excluded. Even with this criterion in place, there was room
for differing interpretations among group members, which led to additional discussion to clarify each criterion. After
developing our CAT table, we were constantly making decisions to guarantee a strong, evidence -based systematic
review of the specific question we strived to answer. It was difficult for us to compare results for two reasons: 1)
each article covered different pieces of psychometric data (although many were comparable) and 2) each
measurement of lymphedema was not comparable as some measured limb mass while others measured volume,
while others measured differences between lymph fluid and other fluids. During our writing of the summary of key
findings and implications, we perceived that it was difficult to reduce redundancy with our information because our
results were mostly unambiguous.
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Once we finished our first draft of the paper, we met again with Shaffer on February 10, 2017. This
meeting allowed us to verbalize our written conclusions and findings. We felt better prepared than we had
anticipated, as we were still unsure if we were correctly understanding the plethora of new lymphedema terms along
with all the psychometric data presented in the studies. When we explained the findings to Shaffer, they were well
received and understood. The biggest challenge of this process was translating our newfound knowledge into
practice. Shaffer’s expectation was to use this systematic review to present to her supervisors to convince insurance
companies for further coverage of the L-Dex. Unfortunately, insurance policies are relatively well established and
although policies oftentimes change, it is customarily a long and slow process. We received support for our research
and our findings from our partnering clinician and Olsen. This support provides us with an optimistic outlook on
how further research can support the development and implementation of the best lymphedema assessment tools.
Advocating for our conclusions combined with reaching the audience we intended demonstrated the importance of
synthesis and knowledge translation. Shaffer, Olsen, and Fustgaard all concluded that this research would be helpful
to present to insurance providers, but that more ongoing, rigorous evidence is needed to support the need for BIS. As
new researchers, we felt empowered to know that our study is being utilized by seasoned practitioners.
Recommendations for future research
According to her responses to our questionnaire, Shaffer would like to see more longitudinal studies
tracking client outcomes with tools that have the potential to detect lymphedema earlier than previously used tools.
Fustgaard corroborated this by stating in her response to our outcomes questionnaire, “…payers desire…more
evidence showing that subclinical detection has an impact on outcomes.” Based on information we found while
researching monitoring lymphedema with assessments, we concur that more data on subclinical lymphedema is
important. It is possible that the sensitivity of an assessment tool may help to prevent the development of clinical
lymphedema with early detection (Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al., 2009; Hidding et al .,
2016). Both self-report (Czerniec et al., 2010) and BIS (Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al., 2009;
Hidding et al., 2016) were identified as sensitive assessments in our research. A thorough literature review on the
subject of early detection of lymphedema should be conducted. Other research including single case studies and
randomized control trials would also contribute to the information available on early detection.
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New technology continues to be developed every day. The L-Dex is a relatively new technology when
compared to water displacement and circumferential measurements to measure lymphedema. As we learned in
speaking to Shaffer (personal communication, February 10, 2017) and Fustgaard (personal communication, April
10, 2017), in order for a new treatment or assessment to be covered by insurance, it must go through different levels
of billing codes. The code determines whether a particular insurance will cover none, part, or a ll of the cost of the
coded item. Research as well as use in practice determines the billing code and whether insurance covers the
assessment. This process of checks and balances takes time, so a new technology that is developed needs research to
support its effectiveness it will be covered by insurance. It is important when considering lymphedema assessments
to identify new technologies that may not be currently used in clinical practice or covered by insurance. Robotic 3D
scanning was a topic of a few articles we located during our search (Chromy,2015; Öhberg & Holmner-Rocklöv,
2014; Santin & Ward 2014 ). Research on this technology may expand. It is important that researchers and clinicians
remain aware and open to the possibility of new and possibly better instruments to measure lymphedema.
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LYMPHEDEMA REHAB CLINICS

FOR MORE
INFORMATION
please speak with your
occupational or physical
therapist at MultiCare or
visit the following websites:
●

Impedimed.com

●

multicare.org/rehabilitationservices-lymphedema/

Sources:
●

Impedimed.com

●

soundideas.pugetsound.edu/student_pubs/
Search Ramolete, Wyatt, Enyeart & Foxlee

MultiCare Covington Clinic
17700 SE 272nd StCovington, WA 98042
p 253-372-7030
f 253-372-7032
MultiCare Gig Harbor Medical Park
4545 Pt- Fosdick Dr- NW
Gig Harbor, WA 98335
p 253-530-8122
f 253-530-8126
MultiCare Good Samaritan Hospital
401 15th Ave SE
Puyallup, WA 98371
p 253-697-7900
f 253-697-5180
MultiCare Regional Cancer Center Tacoma General Hospital
315 Martin Luther King Jr- Way
Tacoma, WA 98405
p 253-403-1040
f 253-403-4873

Appendix A

LYMPHEDEMA
ASSESSMENTS
L-Dex Device (Bioimpedance)
versus
Circumferential Measurements

Definition: the use of a tape to measure the
circumference of a limb at specific locations.
These measurements are used by your
therapist to calculate limb volume and to fit
compression garments
Impedimed.com

Impedimed.com

Why should I care which
lymphedema assessments
my therapist uses?
●

●

●

It helps to ensure that you are
getting the treatment that is
conducive to your needs.
Because of varied accuracy of
measures, you may be able to
treat symptoms of lymphedema
earlier.
It impacts the amount of time you
have to spend in a clinic to be
treated

L-DEX DEVICE

Pros:

Definition: this device measures the
electrical impedance of biological tissue in
response to an applied alternating current.
In the presence of lymphedema, the
applied current will travel predominantly
through the accumulation of lymphatic
fluids.

●

Well-known

●

Standards are established

●

Easy to use

Pros:

●

Early detection of lymphedema

●

Can detect differences between
non- lymphatic fluids and lymphatic
fluids

●

Can detect small differences in
the amount of lymphatic fluid

●

Reliable and valid when compared with
gold standards.

●

Time-efficient (takes less than
5 minutes to administer)

●

Easy to use

Cons:

●

MultiCare charges $70 for this,
unless your insurance covers the
cost

●

Cannot be compared with other
assessments (for validity, if the
first assessment was done using
L-Dex, subsequent re-assessments
should be done with L-Dex as well)

Cons:
●

Cannot detect small changes in fluid

●

Cannot differentiate between
different forms of edema

●

Training is required

●

Takes at least 15 minutes to administer

●

Should be retested at same time of
day with same tool and same
therapist
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Appendix B
Lymphedema In-Service Presentation

Critically Appraised Topic:

Comparisons of Lymphedema
Assessments
Jessica Enyeart, Cullyn Foxlee, Divina Ramolete, Connie Wyatt

Purpose
To review and critique the research comparing lymphedema assessments in
order to determine if BIS truly is the best instrument used in practice, or if
other assessments are shown to be better.
To utilize the evidence in such a way that the L-Dex may have more potential in
becoming a covered lymphedema assessment by federal insurance
companies.
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Research Question
How do bioimpedance spectroscopy (BIS),
circumferential measurements (CM), and
perometry (OP) compare to one another based on
reliability, validity, cost, and time-eﬃciency for
measuring unilateral lymphedema (LE)?

THE RESEARCH
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Overview of the Research Criteria
Inclusion Criteria:
LE of arms and legs, secondary LE, unilateral lymphedema, BIS, CM, perometry (including
infrared optoelectronic volumetry/perometry) and studies done anywhere in the world.
Exclusion Criteria
Primary LE, non-human subjects, self-assessment, children, articles older than 1990, head/
neck LE, studies solely measuring early diagnosis or detection of breast cancer-related
lymphedema (BCRL), water volumetric measurements (if not compared to CM, BIS or
perometry), and tonometry if not within a systematic review/meta-analysis.

OUR FINDINGS
● 1504 articles found
● 1400 articles rejected
● 79 articles were duplicates
● 29 total articles reviewed and placed into our critical
appraisal of topics table
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HISTORY OF LYMPHEDEMA GOLD STANDARD ASSESSMENTS

CM v. BIS v. OP
Circumferential measurements (CM), water displacement (WD), and bioimpedance (BIS) are highly
recommended due to their reliable and valid psychometric properties and clinical utility (Perdomo et al.,
2014).
WD and CM, regarded as the former gold standards to measure lymphedema were commonly compared.
WD and CM (as the historical gold standards) provided a comparison in the literature to assist in determining
the psychometric properties of OP and BIS.
CM and perometry (OP) demonstrated high inter-rater reliability and intra-rater reliability when compared to WD
which did not have as high inter-rater and intra-rater reliability (Deltombe et al., 2007).
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CM v. BIS v. OP (continued)
Strong correlations found between CM and OP; moderate/strong correlations between CM and BIS
methods. (Ridner et al., 2007 and Mayrovitz et al., 2000)
BIS and OP demonstrated relatively poor limits of agreement due to having diﬀerent units of
measurement. (Ward et al. 2009a)
OP measures total arm volume
BIS speciﬁcally measures extracellular ﬂuid

BIS can detect localized lymphedema more readily than OP.

(Czerniec, et al., 2009)

Patients assessed with CM had sig. higher incidence rates of clinical LE (36.4%) compared to BIS (4.4%)
(Soran et al., 2014)

BIS Pros
+ Reliable: High Inter-rater Reliability

(Jain et al., 2010)

+ Valid for early detectiuon (Shah et al., 2013) and measuring leg volume changes (Moseley et al.,
2002)

+ More Time-Eﬃ cient

(Ridner et al., 2007)

+

CM: 25 min

+

BIS via Impedimed Device: 6 min

+ Client & Clinician Preferred (Ward,
+ Economically
Beneﬁ cial (Bilir et al., 2012)
2006)

+

Clinical utility & Feasibility (Laidley & Anglin,
2016)
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BIS Pros (continued)
+ Level of sensitivity: Ability to detect lymphedema earlier than other assessment methods
(Bilir et al., 2012; Czerniec et al., 2010; Czerniec et al. 2009; Hidding et al., 2016)

+

Ideal measurement for early stages of lymphedema (Shah et al. 2013; Bundred et al. 2015)

+

Ability to diagnose subclinical LE (Soran et al., 2014; Laidley & Anglin, 2016)

+ Eﬀective for later stages (Bundred et al., 2015)
+ Eﬀective tool for diagnosis of well-established BCRL (Seward et al., 2016)
+ Capacity to discriminate between diﬀering ﬂuids within the limbs: ECF and other ﬂuids
(Czerniec et al., 2009)

+ Overall literature suggested that BIS may be the most suitable assessment in comparison

BIS Cons
Seward et al. (2016) claimed that there is not enough evidence to conclude that BIS detects
breast cancer related lymphedema earlier than other measurement techniques
Contraindicated for clients who are pregnant or have pacemakers
L-Dex machine does not measure UE lymphedema in men
Expensive: Medicare in the Noridian Region JF (our region) does not cover costs
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IMPLICATIONS

Implications for Patients w/Lymphedema
BIS would be the preferred assessment to measure preoperative baselines because its high sensitivity allows for
earlier detection of lymphedema (Bundred et al., 2015; Shah et al., 2013)
BIS has the ability to carefully monitor LE, diagnose subclinical LE, and initiate early intervention, thus reducing the
incidence rates of clinical LE (Soran et al., 2014)
Early diagnosis of lymphedema via BIS has shown potential to lead to a better prognosis because treatment can be
started sooner rather than later, resulting in overall lower total treatment costs (Bilir et al., 2012)
Evidence shows that treatment of lymphedema implemented earlier may prevent chronic lymphedema (Bundred et al.,
2015)

BIS is faster: provides ease of scheduling for consumers and more $me to treat in session

(Ridner et al., 2007)
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Implications for Occupational Therapy
OTs must use discretion and decide if implementation of these measurement tools are integral to the
ethics of their practice and the needs of their client population.
Considering the pros of BIS found in our research may:
Allow lymphedema specialists (OTs & PTs) to be more certain that they are using valid and reliable
assessments in order to provide optimal care for clients.
Impact clinical reasoning to select an assessment that is in the best interests of their clientele.
Focus sessions more on treating lymphedema and meeting client needs rather than spending a majority
of the time assessing lymphedema.
A key factor in determining between acute and chronic lymphedema (Bundred et al., 2015).

Lead to early detection

Implications for Researchers
Many studies noted that lymphedema is not well deﬁned
Diﬃcult to compare among studies
Limited blinded and RCT studies (Hidding et al, 2012; Impedimed correspondence)
However, in an example when blinding was partially utilized, there was potential for inaccurate reliability
results (Sander et al., 2002).

BIS via L-Dex measures unilateral lymphedema only
Limited accuracy for bilateral lymphedema (Warren et al., 2007).

Studies with more thorough speciﬁcity and sensitivity to deﬁne more precisely appropriate cut oﬀ
values for leg lymphedema (York et al., 2009).
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Implications for Evidence Researchers

● Robotic 3D scanning found among literature

○ A new technology that may be eﬀective in lymphedema measurement.

● Future research should be conducted on early detection and diagnosis of
lymphedema as well as self-report and robotic measurements.

CURRENT PROBLEM: Insurance Coverage
Currently, Heidi Shaﬀer is having issues with federal insurance companies such
as Medicare, Medicaid, and Tricare NOT covering use of the L-Dex.
According to Impedimed’s insurance representative, Washington is located in
the JF Noridian Medicare region, which does not provide consistent
coverage of BIS measures.
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Retrieved via
Impedimed Insurance Representative

WHY?
Generally we see Medicare nationally covering BIS. Unfortunately the Medicare
Administrative Contractor (MAC) of our Noridian region covers BIS sporadically.
Impedimed plans to continue building an evidence base, supporting positive clinical outcomes associated
with their technology.

New Technology: BIS received a CPT-1 code in Jan. 2015
This calls for MORE studies with stronger rigor
Random Control Trials
Reliable and Clear Methods
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Recommendations to Acquire Medicare Coverage
The regional MAC needs to see compelling clinical evidence
relating to positive health outcomes.
HOW CAN WE DO THAT?
More research
Impedimed is currently conducting RCTs and collaborating with national clinici ans
to analyze their client outcomes.

Target private insurance companies to advocate for BIS use

Raise community awareness of the benefits of BIS for lymphedema
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Appendix C
Outcome Measures

Questionnaire – HEIDI SHAFFER
Lymphedema measurements: Which is most valuable for best practice?
Thank you for meeting with us. It would enhance our project if you would answer these questions based on the
information we discussed. By filling out this form you acknowledge that we will use the information from these
answers in our project and it will not be anonymous.


Did you learn anything new from the information we presented? If, yes, what was the new information?
Yes, I learned that many states do have coverage for the LDex measurement tool and I learned some ways
to assist with our state coverage. I learned more about the accuracy of the LDex measurement tool.



Is there anything you feel we missed or did not consider?
I think you all did a great job of assessing the tools we currently use as well as some other tools we use
less. I feel confident that the L-Dex is an excellent tool to use. I also feel that in the future this tool will be
more readily covered by insurance.



What would you like to see considered in future research?
I feel it’s good to stay current with new measurement tools that might be on the horizon. Insurance policies
and coverage consistently change, so it would be good to stay abreast to those changes. It would be great to
see longitudinal studies using various tools and see how patient outcomes are improved with early
lymphedema detection.



Will the information presented change how you advocate for coverage for lymphedema measurements?
Absolutely. It’s great to know that we can advocate for coverage and change with the insurance companies
and it takes studies like this to make those changes.



Do you have any further thoughts after our discussion?
My thoughts are for early detection and advocacy for measurement tools to prevent lymphedema. The tools
can also be used to show outcomes with therapy. For example, true measurements for before therapy and
improvement after. Excellent tool for insurance companies and demonstrating positive outcomes with this
population.
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Questionnaire – SHERRI OLSEN
Lymphedema measurements: Which is most valuable for best practice?
Thank you for meeting with us. It would enhance our project if you would answer these questions based on the
information we discussed. By filling out this form you acknowledge that we will use the information from these
answers in our project and it will not be anonymous.


Did you learn anything new from the information we presented? If, yes, what was the new information?
No



Is there anything you feel we missed or did not consider?
No



What would you like to see considered in future research?
Nothing that I can think of



Will the information presented change how you advocate for coverage for lymphedema measurements?
No



Do you have any further thoughts after our discussion?
Thank you for all the updated information and work you did to identify payer information.
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Questionnaire – MAREN FUSTGAARD
Lymphedema measurements: Which is most valuable for best practice?

Thank you for meeting with us. It would enhance our project if you would answer these questions based on the
information we discussed. By filling out this form you acknowledge that we will use the information from these
answers in our project and it will not be anonymous.


Did you learn anything new from the information we presented? If, yes, what was the new information?
Yes, I learned how the research team will be rolling out their results to have an impact on regional
providers



Is there anything you feel we missed or did not consider?
As we discussed, I think it’s helpful to make it clear that Medicare generally pays for the product
nationally, but individual regions don’t tend to pay, as opposed to making the blanket statement that
Medicare isn’t covering. The changes to the slides we discussed do a good job clarifying this



What would you like to see considered in future research?
One of the biggest barriers we find with commercial payers I desire for more evidence showing that
subclinical detection has an impact on outcomes



Will the information presented change how you advocate for coverage for lymphedema measurements?
I like the idea of working with researchers such as your team to approach regional clinics, so going forward



Do you have any further thoughts after our discussion?
Thanks for taking the time to meet!
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Suggested Brochure Outcomes Questions

The purpose of the following questions is to facilitate gathering information on the use of the informational
brochures created and distributed. These questions are intended to be answered three months, six months, and then a
year after brochures were initially provided by research team. We encourage clinicians to create their own
monitoring outcomes tools.

1. How many brochures were taken by patients in the first (3 month, 6 month, 1 year) period?
2. Where were brochures placed?
3. From what location were the most brochures taken?
4. Did patients ask any clarifying questions on the brochures? If so, what were they?
5. Was there a change in the number of people who chose CM and/or BIS after brochures were made
available?

LYMPHEDEMA ASSESSMENTS
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O N I YE R S ITY of

School of Occupational Therapy and Physical Therapy
1500 N. Warner CMB #1070
Tacoma, WA 98416-1070

PUGET
SOUND

Occupational Therapy Program On-Site Clinic
Consent for ANY and ALL Images
PbotograpbyNideograpby/Phone
0

Faculty/Studlnt Therap\st
Name

_

Position

5-,

I hereby give permiss,

Parent/Guargian Name

_

•

\d)

Id/ward

to appear as a subject in an image, such as videotapes, photographs, and/or smartphones, etc. while at the
School of Occupational Therapy and Physical Therapy of the University of Puget Sound.
The purpose of the images has been explained to me. I also understand that the images will be
under the control of the University of Puget Sound Faculty. In addition, I understand that this consent is
specifically for: (CIRCLE OR WRITE IN ALL THAT APPLY)

c inic/classroom/research study/project)
I understand that first names may be used in these images, with which there is no way to try to
conceal the identity of the subjects. I also understand that I may cancel this consent by written notice and
that this cancellation is without penalty and will in no way affect my future care and services, or academic
standing.
I have had the opportunity to ask question to obtain the kind of information I need to make such
a decisio \
•

A

.

ill,

·

L{-5 it'

Signature of Subject (if applicable

Date

Signature of Parent or Guardian (if applicable)

Date

'Signature of Subjct Advocate (if applicable)

Date

'"'If

••

Phone: 253-879-3281 option#1; Fax: 253-879-2933; Email:otclinic@pugetsound.edu
Revised 11/04/14 SDD
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CONS ENT FOR M
4/10/17
Dear lmpedimed,
We (UPS OT636 Research Group) have permission to use photos and insurance information
from lmpedimed resources. We will ensure that all materials we use from your company is
authentic and cited appropriately.

Thank you,

Divina Ramolete

;/}

Ln

0

tJ l//10/ 2017

Cullyn Foxlee

Connie Wyatt

cfj,

_C_it_L·Jr_#

Jessica Enyeart

/_I'?- __

0_,1/1--0

-'f/ro/n

Date:

Signature:

Date:

u/ . ., 0 ... f t
_

Permission for Scholarly Use of Thesis
To properly administer the Research Repository and preserve the contents for future use, the University of Puget
Sound requires certain permissions from the author(s) or copyright owner. By accepting this license, I still retain
copyright to my work. I do not give up the right to submit the work to publishers or other repositories. By accepting
this license, I grant to the University of Puget Sound the non-exclusive right to reproduce, translate (as defined below),
and/or distribute my submission (including the abstract) worldwide, in any format or medium for non -commercial,
academic purposes only. The University of Puget Sound will clearly identify my name(s) as the author(s) or owner(s)
of the submission, including a statement of my copyright, and will not make any alteration, other than as allowed by
this license, to my submission. I agree that the University of Puget Sound may, without changing the content, translate
the submission to any medium or format and keep more than one copy for the purposes of security, back up and
preservation. I also agree that authorized readers of my work have the right to use it for non-commercial, academic
purposes as defined by the "fair use" doctrine of U.S. copyright law, so long as all attributions and copyright
statements are retained. If the submission contains material for which I do not hold copyright and th at exceeds fair use,
I represent that I have obtained the unrestricted permission of the copyright owner to grant the University of Puget
Sound the rights required by this license, and that such third-party owned material is clearly identified and
acknowledged within the text or content of the submission. I further understand that, if I submit my project for
publication and the publisher requires the transfer of copyright privileges, the University of Puget Sound will
relinquish copyright, and remove the project from its website if required by the publisher.

Name:

Jessica Enyeart

Date:

5/12/17

Cullyn Foxlee

Date:

5/12/17

Divina Ramolete

Date:

5/12/17

Connie Colleen Wyatt

Date:

5/12/17

Jessica Enyeart, OTS

Name:

Cullyn Foxlee, OTS

Name:

Divina Ramolete, OTS

Name:

Connie Colleen Wyatt, OTS
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